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CHAPTER 1 
INTRODUCTION 
 
Blood has fascinated human beings from ancient times. Egyptians bathed in it, 
arestocrates drank it, authors and playwriters used it as themes and modern humanity 
transfused it. The road to an efficient, safe and uncomplicated transfusion technique 
has been rather difficult, but due to scientific developments, great progress has been 
made over the last decades. 
  
Blood is a living tissue composed of cells and plasma. Cells which include red blood 
cells, white blood cells and platelets constitute about forty five percent of the blood 
volume; while plasma accounts for the remaining fifty five percent. About seven 
percent of a person‟s weight is blood and the volume of blood varies according to 
height and weight. 
 
Once regarded as a miracle procedure, blood transfusion is now a routine life-saving 
process. In an age in which spectacular medical advances have become frequent 
occurances, field of transfusion medicine has somehow remained overshadowed. 
Attention is drawn to transfusion practices only and when untoward incidents come to 
light during blood transfusion. Yet, blood an essential human tissue is donated to and 
received by thousands of people each day to save lives. In  India the study conducted 
by a group of experts on the directive of supreme court  observed that for a population 
of over 100 crores hardly 4.5 million units of blood is available against a demand of 8 
million units, thus leaving a gap of 3.5 million units. To meet such huge demand 
supply gap regorous blood donations and well established blood banks are the need of 
time. However, in India, as in many developing countries, officially recognized blood 
banks are rare and far apart. The strain on blood bank is not merely the volume of 
blood needed but also availability of „safe‟ blood as and when needed. 
 
The transfusion of blood began with the use of whole blood and continued for many 
years. Now-a-days, blood is separated into its cellular and protein components to be 
used in specific blood disorders and illnesses. However, unfortunately these blood 
products/components are associated with the risk of transmission of viral, parasitic 
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and bacterial diseases. The degree of problem caused by these microbial agents is 
directly related to their endemicity in a particular area. Handling and storage of blood, 
its components and products at room temperature as well as 4ºc may provide 
sufficient time and opportunity for microbial growth. There are two major hurdles in 
providing a very efficient and risk free transfusion therapy. 
(1) Shortfall on the technical side; both in terms of trained technical personal as well 
as modern sophisticated instrumentation. This is specifically a very severe 
problem in remote regions of our country where majority of rural population 
reside. 
(2) Dependence on same source of high risk professional blood sellers and only 
changed the title of professional blood sellers to relative donors or replacement 
donors. 
 
Since the detection of Human Immuno Deficiency Virus (HIV) infection in Tamil 
nadu in 1986 there has been sudden awakening about the fact that a life saving 
regime for a patient in need of blood transfusion can lead to slow but painful death in 
form of Acquired Immunodeficiency Syndrome (AIDS). Blood transfusion is the 
most efficient way of transmission of HIV. Even a small transfusion of infected 
blood results in virtually 100% seroconversion. 
 
Besides AIDS, a number of microbial infections; viral, bacterial as well as parasitic 
in nature are known to be transmitted via blood. The list dose not end here and new 
infections are making entry into it. Latest suspect is human form of Bovine 
spongiform encephalopathy (BSE) or “mad cow” disease – a prion disease of human, 
also known as „varient crutzfeldt-Jacob disease‟ or vCJD. Prions are present in 
peripheral lymphatic tissues to a greater extend than classical CJD. (Ganem, 2004; 
Bergman, 1995) 
 
Since the time when Dr. Bernard Fantus, Professor of Pharmacology, University of 
Illinois established the first blood bank in 1937, the objective has been to provide 
quality blood in required quantity. There are some genetically inherited diseases or 
some medical situations where a person can survive only if one is given „multiple 
blood transfusions‟. A multiple blood transfusion is prescribed under variety of 
situations namely; Thalassaemia, Hemophilia, Heamodialysis, Surgical 
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multitransfusion and Leukemia. Since the individuals are subjected to multiple blood 
transfusions, it is obvious that they fall into „high risk‟ group likely to be more 
vulnerable to various microbial infections caused by blood transfusion therapy. 
 
Present study is aimed at comparing prevalence of same of the microbial infections 
such as HIV, hepatitis, bacterial infections and parasitic infection mainly in different 
cohorts of multitransfused individuals with each other and also with the control set of 
blood donors who are proclaimed to be „healthy‟.  
   
The prevalence of viral markers such as HIV, HBsAg and HCV antigen along with 
Veneral Disease Laboratory Research (VDRL) test for detection of syphilis are 
„indices‟ of safe blood as per the guideline of drug and cosmetic act of India. 
However, due to lapse in quality control as well as blood donation during „window 
period‟ of infection result in transmission of these antigens to the recipient. In such 
context, patients with history of multiple blood transfusions can be considered at 
„high risk‟ of receiving such contaminated blood. 
 
For a comparative study of different cohorts of multitransfused patients for various 
microbial markers as well as biochemical parameters, various blood analysis methods 
were used. This included Enzyme Linked Immunosorbent assay (ELISA) for various 
antigens, Polymerase Chain Reaction (PCR) based analysis for detection of HBsAg 
and HCV antigens and related biochemical analysis for various cohorts. 
 
 
 
 
 
4 
 
OBJECTIVES 
 
1. To study prevalence of microbial infections in different cohorts of multi-
transfused patients namely thallasaemics, haemodialysis patients, 
hemophiliacs, surgical multitransfused and leukemia patients. 
2. Comparative studies on prevalence of microbial infections in healthy donors 
and multitransfused patients. 
3. To study correlation between various haematolological and biochemical 
parameters with presence of microbial infections in individual cohort. 
4. To determine statistical significance of results obtained within different 
cohorts and in healthy donors. 
5. To perform molecular analysis of some of the seropositive patients by 
advanced techniques like polymerase chain reaction (PCR). 
6. To compare prevalence of microbial infections in various cohorts of 
multitransfused patients of Saurashtra region with that at global level from 
literature reviews. 
  
 
 
 
CHAPTER 2 
REVIEW OF LITERATURE  
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CHAPTER 2 
REVIEW OF LITERATURE 
 
Blood is a fluid pumped by the heart that circulates throughout the body via the 
arteries, veins, and capillaries. An adult male of average size normally has about 6 
quarts (5.6 liters) of blood. The blood carries oxygen and nutrients to the body tissues 
and removes carbon dioxide  
 
COMPONENTS OF BLOOD         
 
 
Blood is a mixture of cells and watery liquid, called plasma that the cells float in. It 
also contains other things like nutrients (such as sugar), hormones, clotting agents, 
and waste products to be flushed out of the body. 
There are three kinds of cells in the blood: red blood cells, white blood cells, and 
platelets. Red blood cells carry oxygen from the lungs throughout the body, white 
blood cells help fight infection, and platelets help in clotting.  
 
RED BLOOD CELLS 
Red blood cells (also called erythrocytes) are the most numerous, making up 40-45 
percent of one's blood, and they give blood its characteristic color. Red blood cells are 
shaped like tiny doughnuts, with an indentation in the center instead of a hole. They 
contain a special molecule called hemoglobin, which carries the oxygen. In the lungs, 
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where there is a lot of oxygen, the hemoglobin molecules loosely bind with oxygen. 
Each molecule of hemoglobin contains four iron atoms, and each iron atom can bind 
with one molecule of oxygen, allowing each hemoglobin molecule to carry four 
molecules of oxygen. In the capillaries, where there is little oxygen, the hemoglobin 
readily sheds the oxygen it is carrying and allows it to be absorbed by the body's cells. 
The iron in hemoglobin is what makes blood red.  
 
WHITE BLOOD CELLS 
White blood cells (leukocytes) are the body's mobile warriors in the battle against 
infection and invasion. There are three types of white blood cell: granulocytes, 
lymphocytes, and monocytes. There are, in turn, three kinds of granulocyte: 
neutrophils, eosinophils, and basophils. (Granulocytes are called so because they 
contain granules that hold digestive enzymes.) Neutrophils kill invading bacteria by 
ingesting and then digesting them. Eosinophils kill parasites, and are involved in 
allergic reactions. Basophils also function in allergic reactions, but are not well 
understood. Lymphocytes are key parts of the body's immune system. There are two 
kinds of lymphocyte: T cells and B-lymphocytes. T cells direct the activity of the 
immune system. B-lymphocytes produce antibodies, which destroy foreign bodies. 
Monocytes, the largest kind of white blood cells, enter the tissues of the body and turn 
into even larger cells called macrophages. They eat foreign bacteria and destroy 
damaged, old, and dead cells of the body itself.  
 
PLATELETS 
The blood cells called platelets (thrombocytes) help blood to clot, in several different 
ways. When bleeding occurs, platelets clump together to help form a clot. Also, when 
they are exposed to air (as they would be by a wound), platelets start breaking down 
and release a substance into the bloodstream. This substance starts a chain of chemical 
events that eventually causes a protein in the blood, fibrinogen, to turn into a different 
substance, fibrin, which forms long threads. These threads tangle up red blood cells to 
help from a clot, or scab, over the wound. In their "resting" state, platelets look like 
two plates stuck together (hence the name). When "activated" and helping to form a 
clot, they change shape and look like tiny roundish blobs with tentacles. At only two 
to three microns, they are the smallest kind of blood cell.  
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PLASMA 
Plasma is a clear, straw-colored liquid that carries the blood cells and various 
hormones, nutrients, and so on through the body. It makes up a little Plasma is about 
90 percent water. Much of the other ten percent comprises various kinds of protein 
molecules, including enzymes, clotting agents, immunoglobulin, and proteins that 
carry hormones, vitamins, cholesterol, and other things the body needs. Plasma also 
contains sugar (glucose) and electrolytes like sodium, potassium, and calcium, as well 
as other things like the aforementioned hormones, vitamins, and cholesterol. 
 
Blood cells are produced in the bone marrow, a jellylike substance inside the bones 
that is composed of, among other things, fat, blood, and special cells that turn into the 
various kinds of blood cells. In children, the marrow of most of the bones produces 
blood. But in adults, only the marrow of certain bones -- the spine, ribs, pelvis, and 
some others -- continues to make blood. Bone marrow that actively produces blood 
cells is called red marrow, and bone marrow that no longer produces blood cells is 
called yellow marrow.  
 
All blood cells come from the same kind of stem cell, which has the potential to turn 
into any kind of blood cell. These stem cells are called pluripotential hematopoietic 
stem cells.  
 
Blood transfusions were not possible until Karl Land Steiner first identified the major 
human blood groups - namely O, A, B, and AB -- in a series of experiments in 1901 
that earned him the Nobel Prize.(At the time, Land Steiner identified only groups A, 
B, and O; further analysis, two years, later revealed AB.) 
 
There are many other antigens on the red cell surface. The most important is the Rh 
factor. A person is defined as either Rh positive or Rh negative depending on the 
presence of the primary Rh antigen on the red cell. In contrast to ABO antigens, 
however, a person only develops anti-Rh after exposure to Rh-positive red cells 
through transfusion or pregnancy. Modern blood-banking technology uses highly 
sensitive tests to properly identify and match blood between donor and recipient. 
(Greer, 2004).  
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What is a Blood Transfusion? 
Blood transfusion is withdrawal of blood or its constituent parts from healthy donors 
and given to oligaemic patients. 
 
Sometimes a person will have some of their own blood drawn & stored before having 
surgery & re injected after surgery this is called autologous blood transfusion  
 
A blood transfusion is a safe, common procedure in which blood is given to you 
through an intravenous (IV) line in one of your blood vessels. Blood transfusions are 
done to replace blood lost during surgery or a serious injury. A transfusion also may 
be done if your body can't make blood properly because of an illness.  
 
During a blood transfusion, a small needle is used to insert an IV line into one of your 
blood vessels. Through this line, you receive healthy blood. The procedure usually 
takes 1 to 4 hours, depending on how much blood you need. 
 
Blood transfusions are very common.. Most blood transfusions go well. Mild 
complications can occur. Very rarely, serious problems develop.     
 
Millions of lives are saved each year through blood transfusion. In many countries 
however people still die due to an inadequate supply of blood & blood products. 
 
This has a particular impact on women (as a consequence of pregnancy related 
complications), children (malnutrition, malaria, severe life- threatening anemia, 
hemophilia, and thalassemia) and trauma victims especially poor & disadvantaged. 
 
History of Blood Transfusion 
From the earliest recorded, Blood has been a point of fascination and mystery. Early 
in time we see Blood represented as a source of passion in humans. We often hear 
"hot Blooded," "cold Blooded" and "bad Blood." These familiar expressions are found 
in every language, and are in common use the world over today. 
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As history records, Bloodletting was a common medical practice until the early 
1800's. This combination of superstition and desire to do something meaningful for 
sick people, no doubt led to many deaths and the spread of disease. "Thinning the 
Blood," was also very popular, fruitlessly useless, and sometimes deadly.  
 
Early on, 'Blood transfusion' meant direct donor-to-patient transfusion. This practice, 
however, was frequently disastrous because there was no quality knowledge of Blood 
types, and compatibility. At first, even animal- to- human transfusion was tried. (Farr, 
1980).  
 
In 1901, Karl Land Steiner, an Austrian physician, whom we see as the most 
important individual in the field of human Blood, documented the first three human 
Blood groups (based upon substances on the Blood cells), A, B and O. Without this 
discovery and the subsequent research, there would be no Blood banking.   
 
The practice of drawing and storing human Blood is a comparatively new science. 
Borne in these beginnings of human Blood transfusion, the need for storage of the 
rapidly perishable Blood became obvious.  
 
In 1914, long-term anticoagulants, among them sodium citrate, were developed and 
tried in Europe, promising longer term preservation of Blood.  
 
In 1916, Francis Rous and J. R. Turner introduced a citrate-glucose solution that 
permitted storage of Blood for several days after collection. Also, as in the 1915 
Richard Lewisohn discoveries at Mt. Sinai Hospital in New York City, this allowed 
for Blood to be stored in containers for later transfusion, and aided in the transition 
from the vein-to-vein method to direct transfusion. This discovery also directly led to 
the establishment of the first Blood 'depot' by the British during World War I. Oswald 
Robertson was credited as the creator of the Blood depots, basically the forerunner 
Blood banking system that is in use today.  
 
Further, during that same time period, R. Weil demonstrated the feasibility of 
refrigerated storage of anti-coagulated Blood.  
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Early in 1932, the first facility, fully functioning as what would come to be known as 
a "Blood bank," was established in a Leningrad Russia hospital.  
 
In 1936, Bernard Fantus, director of therapeutics at the Cook County Hospital in 
Chicago, established the first hospital Blood bank in the United States In creating a 
hospital laboratory that can preserve and store donor Blood, Fantus originated the 
term 'Blood bank.' Within a few years, hospital and community Blood banks began to 
be established across the United States, some of the earliest documented were in 
Cincinnati, San Francisco, New York and Miami.  
 
In 1940, when he was at Columbia Presbyterian Hospital in New York, Dr. Charles 
Drew, a graduate of McGill University Medical School in Montreal, researched and 
documented a technique for long-term preservation of Blood plasma. By separating 
the liquid red Blood cells from the near solid plasma and freezing the two separately, 
he found that Blood could be preserved and reconstituted at a later date. In addition, 
as a prolific inventor, he was a major contributor to the advancement of Blood 
banking in the United States. In England, he helped supply thousands of units of 
plasma for World War II victims.  
 
Later in 1940, Edwin Cohn, a professor of biological chemistry at Harvard Medical 
School, developed a cold ethanol fractionation, the process of breaking down Blood 
plasma into components and products that were made available for clinical use. This 
was the birth of the Blood product manufacturing industry.  
 
Blood banking began growing rapidly with the return from World War II of 
physicians who had seen the effectiveness of transfusion therapy and began to 
demand that Blood be made available for treatment of their patients.  
 
In 1946, the United States Public Health Service issued the first federal license 
permitting the 'manufacture' of whole Blood.  
 
In 1947, the American Association of Blood Banks (AABB) was formed to "promote 
common goals among Blood banking facilities and the American Blood donating 
public. Essential to this success story were the goals to support and encourage 
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continued Blood research, to facilitate the exchange of scientific information, and to 
develop standards of practice for Blood banks. This commitment to universal 
standards and communication changed the business of Blood banking forever.  
 
By 1948 the American [National] Red Cross had began operating a comprehensive 
program to collect and distribute Blood.  
 
By 1950, the United States Blood collection system had grown to approximately 
1,500 hospital Blood banks, 46 community Blood centers and 31 American Red Cross 
regional Blood centers, among others.  
 
Also in 1950, Carl Walter and W. P. Murphy, Jr. introduced the plastic bag for Blood 
collection and storage, replacing breakable glass bottles with rugged plastic bags. 
These plastic bags allowed, among other things, economical ultra low temperature 
freezing of Blood and Blood products.  
 
Additionally in 1950, an active year in Blood banking history, the use of glycerol 
cryoprotectant for freezing red Blood cells became widespread.  
 
In 1951, the AABB Clearinghouse (now the National Blood Exchange) was 
established, providing a centralized system in the United States for safely exchanging 
Blood among Blood banks.  
 
By 1962 in the United States, there were 4400 hospital Blood banks, over 120 
community Blood centers and more than 50 American Red Cross Blood centers, 
collecting a total of five to six million units of Blood per year.  
 
1965 - Judith Graham Pool identifies the technique, now known as cryoprecipitation 
for concentrating factor VII from Blood plasma.  
 
1972 - The FDA Bureau of Biologics begins regulating Blood resources. It assumed 
this responsibility from the National Institutes of Health, Division of Biologics 
Standards.  
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1973 - The FDA publishes more precise standards for Source Plasma and requires all 
operating plasmapheresis facilities to apply for and maintain licensure of Blood 
establishments and Blood products and submission to inspection standards.  
 
1974 - The FDA declares Good Manufacturing Practices (GMP's) for the collection, 
processing, and storage of human Blood and Blood components.  
 
1977 - The formal FDA compliance program is established. Annual facility 
inspections are transferred from the FDA Bureau of Biologics to FDA field 
investigators and program supervisors.  
 
1989 - The FDA issues some light weight requirements for computerization of Blood 
related establishments, with higher quality requirements to come.  
 
1992 - The International Plasma Products Industry Association, an influential trade 
group representing Blood manufacturers is formed (primarily of U. S.).  
 
1994 - The European Association of the Plasma Products Industry, a trade group 
representing Blood manufacturers in Europe and the UK, is founded.  
 
In 1996 and 1997 - The United States Government first issued reports suggesting 
problems with the Blood supply, along with suggestions of ways to improve Blood 
safety, including regulatory reform in the Blood processing and Blood banking 
industries. This has become a routine event.  
 
An effort of many years in 1999 produced the implementation by the Blood 
manufacturing community of Nucleic Acid Amplification Testing (NAT) under the 
FDA’s Investigational New Drug (IND) application process. NAT employs a testing 
technology that directly detects the genetic materials of viruses like HCV and HIV 
(Wildmann, 2000). 
 
In the United States today, licensed Blood donation and banking establishments 
include centers that collect, process, store and distribute Blood and Blood products. 
These facilities are engaged in Interstate Commerce, and are therefore regulated under 
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federal law. Standardization, inspection and enforcement are bringing the science of 
Blood banking to an ever newer, more useful and trusted place.  
 
Long term "cryo" storage of Blood and Blood products at hyper low temperatures is 
shaping the story of the future of Blood, Blood products and the safety of the public 
Blood supply. These processes also offer ever more economical autologous Blood 
donation and storage alternatives for those who need and/or can afford them.  
 
Blood Donation 
Blood donation is a process by which a blood donor voluntarily has blood drawn for 
storage in a blood bank, generally for subsequent use in a blood transfusion. 
 
Process 
The process of giving blood involves screening the donor, the actual donation, and a 
brief recovery period. This applies to both whole blood donations and plasmapheresis, 
or donating only. 
Donated blood is tested by many methods, and a typical screening panel includes 
most of the tests below: 
 
Blood Type 
Blood is tested to determine the donor's ABO group (A, B, O, and AB) and Rh type 
(positive or negative). This is critical in selecting compatible blood for a patient in 
need of a transfusion. 
 
Antibody Detection Test 
All donors are tested to determine if their plasma contains unexpected antibodies to 
red blood cell antigens (genetic marker). These antibodies, if not identified, can cause 
problems in a blood recipient. 
 
Tests for Infectious Diseases 
Screening donated blood for infectious diseases that can be transmitted through blood 
transfusion is very important in ensuring safety. A positive screening test in any of the 
following tests for infectious disease is followed by a confirmatory test, since it is 
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possible to have false positive test results. A false positive occurs when the screening 
test is positive but it cannot be confirmed. This means a donor was not exposed to the 
infectious agent being tested for but the screening test was positive. The following 
tests to be performed on each unit of donated blood are required by the Food and 
Drug Administration (FDA): 
 
Hepatitis B Surface Antigen (HBsAg) 
The hepatitis B virus has an inner core and an outer envelope (the surface). The 
HBsAg test detects the outer envelope or surface of the virus. 
 
Hepatitis C Virus Antibody (anti-HCV) 
Two tests are done to detect hepatitis C infection. The anti-HCV test detects 
antibodies to the hepatitis C virus. A positive result suggests the donor has been 
exposed to the hepatitis C virus and may be infectious. 
 
Syphilis Antibody 
Syphilis tests detect the presence of an antibody to the organism Treponema pallidum 
that causes syphilis. This test has been performed on blood donors since shortly after 
World War II when the rate of infection was much higher. The risk of transmitting 
syphilis through a blood transfusion today is very small, since the rate of infection is 
low in blood donors and the organism causing syphilis is very fragile and unlikely to 
survive blood storage. 
 
Human Immunodeficiency Virus 2 (HIV-1/2) Combo Antibody 
HIV-1 and/or HIV-2 virus cause acquired immunodeficiency syndrome, or AIDS. 
HIV-1 is more common in the United States while HIV-2 is prevalent in Western 
Africa. One screens for antibodies to both HIV-1 and HIV-2 viruses.  
 
Autologous donation 
A person who anticipates the need for a blood transfusion at a later date (usually 
because of scheduled surgery) may make an autologous donation, in which their 
blood is stored and later transfused back into its original donor. Besides ensuring the 
availability of compatible blood (especially important for patients with rare blood 
types), this procedure also eliminates the risk of disease transmission from infected 
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donors. Autologous donation is sometimes done by the hospital instead of a 
community blood bank. Eligibility requirements are relaxed for autologous donors, as 
the blood is not used for anyone else. Generally, any patient who is eligible for 
elective surgery with some exceptions such as history of heart disease is eligible for 
autologous donation.  
 
Blood Component Preparation and Therapy 
 
INTRODUCTION 
Modern blood transfusion envisages the optimal use of every blood donation by way 
of blood component therapy. The development of plastic blood collection bags with 
integral tubing, high speed refrigerated centrifuge, deep freezers and cell separator 
machines have made blood component preparation easier and practical. With the more 
advanced chemical techniques (plasma fractionation) various plasma derivatives or 
fractions are also now made available. 
    
List of various blood components and plasma derivatives: 
 
BLOOD COMPONENTS PLASMA DERIVATIVES 
 Red cell concentrate 
              ( packed  red cells) 
 Albumin  
 Leukocyte poor red cell concentrate.  Plasma protein fraction (PPF) 
 Platelet rich plasma (PRP)  Factor VIII concentrate 
 Platelet concentrate  Fibrinogen  
 Granulocyte   concentrate  Immunoglobulin 
 Fresh frozen plasma (FFP)  Other coagulation factors 
 Cryoprecipitate  
 Single donor plasma 
 Cryo – poor plasma 
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Blood component therapy helps in two ways… 
 Economy of blood as one unit of blood can be separated into different 
components and used in different patients according to their indication. 
 Minimizes the hazards of whole blood transfusion. 
 
Preparation of Blood Components 
Various components of blood like red blood cells, platelets and plasma can be 
separated from one another by centrifugation because of their different specific 
gravities. 
 
1. RED BLOOD CELLS 
Red blood cells are prepared by removing approximately 200 to 250 ml of plasma 
from a unit of 450 ml of whole blood or 150 to 175 ml of plasma from a unit of 350 
ml of whole blood. The red cells have approximately heamatocrit of 70-80% and have 
same oxygen carrying capacity as whole blood. 
 
Preparation 
Red blood cells are prepared by… 
1. Sedimentation 
The blood after collection is kept in a refrigerator in a upright position, till the 
red cells settle down and the supernatant plasma is transferred into a transfer 
bag or satellite bag. 
2. Centrifugation 
Blood is collected in double/triple CPDA blood collection bags and after 
balancing bags are centrifuged at 5000*g for 5 minutes at 4-6 degree temp. 
 
INDICATIONS 
1. Severe anemia to reduce chances of circulatory over load. 
2. Hemolytic anemia especially in aplastic crisis. 
3. Various hypo plastic anemias. 
4. Less blood group antibodies in packed cell, so non-specific blood  
i.e. O Negative blood can be given to patients with other groups. 
5. Less plasma proteins with packed cells, so there are minimum aphylactic reactions.  
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Transfusion requirement of each patient should be based on clinical status, rather than 
hemoglobin value or heamatocrit. There are no set hemoglobin levels that indicate the 
need for transfusion. The level of 10 gm/dl has been used as transfusion trigger for 
many years for surgical and leukemia patients, which has now been lowered to 7.5 
gm/dl. 
 
2. LEUCOCYTE POOR RED BLOOD CELLS 
Leukocyte poor red blood cells imply the removal of at least 70%of the leucocytes, 
with a loss of less than 20%of red blood cells. 
 
Preparation 
1. Centrifugation: Inverted centrifugation Double centrifugation 
2. Filtration 
3. Washing of red blood cells with saline. 
4. Freezing and Deglycerolization.  
 
Advantages 
The use of leucodepleted blood products is gaining importance because of the 
scientific evidence that filtered blood products to remove leucocytes prior to 
transfusion prevent or reduce the incidence and severity of adverse transfusion effects 
like:- 
 Febrile non-hemolytic transfusion reaction (FNHTR) 
 Sensitization to blood products (HLA-allo-immunization) 
 Transmission of certain transfusion associated diseases like CMV infection. 
 
3. FRESH FROZEN PLASMA (F.F.P) 
Plasma separated from whole blood, frozen within six hours of collection and stored 
at –20ºC and below. 
 
Indications: 
  Multiple coagulation factor deficiencies 
  Reversal of coumarin drug effect 
  Use in Antithrombin Deficiency 
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  Immunodeficiency syndromes 
  In open heart surgery 
 
4. CRYOPRECIPITATE 
It is the insoluble portion of plasma remaining after the fresh frozen plasma has been 
thawed under controlled conditions. 
 
Composition of cryoprecipitate: 
               CONSTITUENTS                          AMOUNT 
Factor VIII 80-100 Units/Concentrate 
Fibrinogen 150-250 mg./concentrate 
Von-Willebrand Factor 40-70% of original FFP 
 
Indications: 
Cryoprecipitate may be indicated for treatment of: 
  Hemophilia A 
  Von-Willebrands disease 
  Congenital or acquired fibrinogen deficiency 
 
5.  PLATELET RICH PLASMA AND PLATELET CONCENTRATE 
Preparation: 
1. By using CDP-A/or ADSOL or SAG –M triple bags and refrigerated centrifuge. 
2. By using aphaeresis machines (cell separators). 
 
Indications:  
1. A megakaryocytic thrombocytopenia: Leukemia (Kliman et al., 1964) 
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BLOOD TRANSFUSION SAFETY 
Raktabiij – an asura described in our epics glorified the value of blood as he was 
blessed with the ability to have a clone generated automatically with every drop of his 
blood that touches the ground. If we translate this story to modern medicine, blood 
constitutes the lifeline of human body, and can generate life in a moribund soul. With 
nearly 13 million annual unscreened blood transfusions, 95 per cent of blood 
transfusions in India were deemed unsafe by researchers from Northwestern 
University. The WHO estimated that 80 per cent of global population living in 
developing world has access to only 20 per cent of safe blood. Therefore, safety of 
blood transfusion is key to delivery of quality of patient care.  
 
The emergence of HIV in the 1980s highlighted the importance of ensuring the safety, 
as well as the adequacy, of national blood supplies. In many countries, even where 
blood is available, many recipients remain at risk of transfusion-transmissible 
infections (TTIs) as a result of poor blood donor recruitment and selection practices 
and the use of untested units of blood. 
 
The WHO Blood Transfusion Safety (BTS) team supports the establishment of 
sustainable of national blood programmes that can ensure the provision of safe, high 
quality blood and blood products that are accessible to all patients requiring 
transfusion and their safe and appropriate use. In support of this mission, the WHO 
BTS team recommends the following integrated strategy to national health authorities: 
   Establishment of a well-organized, nationally coordinated blood transfusion 
service that can provide adequate and timely supplies of safe blood for all patients 
in need;  
 Collection of blood only from voluntary unpaid blood donors at low risk of 
acquiring transfusion-transmissible infections and stringent blood donor selection 
criteria;  
 Testing of all donated blood for transfusion-transmissible infections, blood groups 
and compatibility;  
 Production of blood components to maximize the use of donated blood and 
enables the provision of therapeutic support for patients with special transfusion 
requirements;  
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 Appropriate clinical use of blood and the use of alternatives, where possible, to 
minimize unnecessary transfusions;  
 Safe transfusion practice at the bedside; 
 
National blood transfusion services  
The provision of safe and adequate blood is the responsibility of government. The 
formation of a nationally organized and managed blood programme should be an 
integral part of each country's national health care policy and health care 
infrastructure. The blood transfusion service (BTS) should be established in 
accordance with an agreed: National blood Policy and plan within a legislative 
framework. It should be responsible for establishing and maintaining a national 
quality system, including the development of guidelines and standards, staff training, 
a data/ information management system and a system for monitoring and evaluation 
of all the blood transfusion activities. 
 
The BTS requires formal government commitment, support and recognition of the 
national health authority as a specific, identifiable programme with a budgeting and 
finance system that can ensure the BTS to fully achieve a stable and adequate blood 
supply. Safe, accessible supplies of blood and blood products cannot be achieved 
without cost. However, an unsafe or inadequate blood supply is ultimately even more 
costly - in both human and economic terms. 
 
Voluntary blood donation  
Safe blood donors are the cornerstone of a safe and adequate supply of blood and 
blood products. The safest blood donors are voluntary, non-remunerated blood donors 
from low-risk populations. Despite this, family/replacement and paid donors, which 
are associated with a significantly higher prevalence of transfusion-transmissible 
infections (TTIs) including HIV, hepatitis B, hepatitis C, syphilis and Chagas disease, 
still provide more than 50% of the blood collected in developing countries. WHO 
advocates and recommends to its member states to develop national blood transfusion 
services based on voluntary non-remunerated regular blood donation in accordance 
with World Health Assembly resolution 28.72, which was adopted in 1975.  
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The key to recruiting and retaining safe blood donors is good epidemiological data on 
the prevalence (and incidence, where possible) of infectious markers in the general 
population to identify low-risk donor populations coupled with an effective donor 
education, motivation and recruitment strategy to recruit new voluntary non-
remunerated blood donors from these populations. A pleasant experience during 
blood donation, good donors care and effective communication between blood centre 
staff and blood donors are all important factors for the retention of safe blood donors.  
 
Testing of donated blood 
Testing of all donated blood for transfusion transmitted infections (TTIs) such as 
HIV, Hepatitis B, Hepatitis C and Syphilis is one of the strategies recommended 
WHO to ensure safe blood. Where appropriate and possible, donated blood should be 
tested for other infections such as Chagas Disease and Malaria. Blood is also tested to 
identify the blood group and for the presence of irregular red cell antibodies before 
transfusion. This is to make sure the patient who will receive compatible blood in 
order to avoid serious hemolytic transfusion reactions.  
 
The inappropriate use of blood and blood products, coupled with the transfusion of 
unscreened or improperly screened units, particularly in countries with poor blood 
programmes, increases the risk of TTIs to recipients. It also widens the gaps between 
supply and demand and contributes to shortages of blood and blood products for 
patient requiring transfusion. Thus, it is necessary to reduce the unnecessary 
transfusions. This can be achieved through the appropriate clinical use of blood, 
avoiding the needs for transfusion and use of alternatives to transfusion. The 
transfusion is deemed appropriate when it is used to treat condition leading to 
significant morbidity and mortality that cannot be prevented or managed effectively 
by other means. The commitment of the health authorities, health care providers and 
clinicians are important in prevention, early diagnosis and treatment of diseases/ 
conditions that could lead to the need for blood transfusion. 
 
Infectious Risks of Transfusion 
Currently, the risk of transmission of infectious diseases through transfusion is 
minimal, because effective preventive strategies, including new laboratory tests, have 
been implemented. Nevertheless, many infectious agents, including viruses, bacteria, 
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and parasites, can be transmitted through blood transfusion. Well-recognized viruses 
include hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), 
hepatitis D virus (HDV), hepatitis G virus/GB-C virus (HGV/GBV-C), human 
immunodeficiency virus types 1 and 2 (HIV-1/2), human T-cell lymphotropic virus 
types I and II (HTLV-I/II), cytomegalovirus (CMV), Epstein-Barr virus (EBV), TT 
virus (TTV), human herpes virus type 6 (HHV-6), SEN virus (SEN-V), and human 
parvovirus (HPV-B19). Bacteria such as Treponema pallidum (the agent of syphilis), 
Yersinia enterocolitica, and Staphylococcus and Streptococcus species (common 
agents of bacterial contamination), and parasites such as Plasmodium species (the 
agent of malaria), Trypanosoma cruzi (agent of Chagas' disease), and Babesia microti 
(agent of babesiosis) have also been reported to be transmitted through blood 
transfusion. In addition, emerging blood-borne pathogens such as hepatitis E virus 
(HEV), human herpes virus type 8 (HHV-8), Borrelia burgdorferi (agent of Lyme 
disease), and the unknown agent of Creutzfeldt-Jakob disease (CJD) and variant CJD 
(vCJD) may pose a threat to the safety of blood. 
 
Infectious agents may be classified into five categories based on transmissibility 
through transfusion, pathogenicity of the agent, availability of donor serologic test, 
and effectiveness of pathogen inactivation. The risk of transmission for the first group 
of agents is minimal because of donor screening and testing, and is normally 
associated with donations collected during the window period. For example, the risk 
of transmission of HIV and HCV in Canada through blood transfusion was estimated 
to be 1 in 752,000 and 1 in 225,000 donations respectively (Chiavetta et al., 2000). 
Infections caused by agents in the second and third group usually present clinical 
diseases in high-risk recipients, such as immunocompromised individuals; however, 
the transfusion transmission risk is also very small because of preventive strategies 
such as universal leukodepletion and solvent-detergent treatment. Transfusion 
transmitted bacterial infections resulting from bacterial contamination of blood 
components is the most common infectious adverse event. Approximately 1 in 2,000-
3,300 units of platelets and 1 in 38,500 units of red cells are contaminated with 
bacteria; however, not every contaminated component causes reactions. The incidence 
of transfusion transmitted bacterial reaction is estimated to range from 1 in 500,000 
units of red cells to 1 in 50,000 units of platelets (Blajchman et al., 1999). 
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Infectious agents in the fourth and fifth group may pose a potential risk following 
transfusion. Although agents in the fourth group have been proved to be transfusion 
transmissible, the pathogenicity of these agents is currently not established. Similarly, 
even though agents in the last group usually cause disease, their transfusion 
transmissibility has not been established.  
Table 1  
 Categories of infectious agents according to transfusion transmissibility, 
pathogenicity, donor test and pathogen inactivation. 
 First 
Group 
Second Group Third 
Group 
Fourth 
Group 
Fifth 
Group 
Agents HBV, 
HCV, 
HIV-1/-2, 
HTLV-I/-II, 
Treponema 
pallidum 
CMV, 
EBV, 
Yersinia 
enterocolitica, 
Staphylococcus 
and Streptococcus 
species, 
Trypanosoma 
cruzi 
HAV, 
HPV-B19, 
HHV-6, 
Plasmodium 
species, 
Babesia microti, 
Rickettsia 
rickettsii, 
Leishmania 
donovani, 
Toxoplasma 
gondii 
HGV/GBV-
C, 
TTV, 
SEN-V 
HEV, 
HHV-8, 
Borrelia 
burgdorferi, 
Ehrlichia 
phagocytophila, 
prions 
Transfusion 
transmissibility 
Established Established Established Established Not established 
Pathogenicity Cause 
diseases 
Cause diseases 
largely in high 
risk individuals 
Cause diseases 
largely in high 
risk individuals 
Not 
established 
Cause diseases 
Donor serologic 
test 
Available Not available Not available Not available Not available 
Effectiveness of 
pathogen 
inactivation 
Largely 
inactivated 
Largely 
inactivated 
Largely not 
inactivated 
Unknown Unknown 
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Noninfectious Risks of Transfusion  
Although Transfusion Transmitted infections have received the greatest attention, 
noninfectious adverse events remain the most common complications associated with 
transfusion. The majority of these noninfectious adverse events are immune mediated. 
Acute immune mediated reactions include acute hemolytic transfusion reaction 
(AHTR), transfusion-related acute lung injury (TRALI), febrile nonhemolytic 
transfusion reaction (FNHTR), urticarial reaction and anaphylaxis. Delayed immune 
mediated reactions consist of delayed hemolytic transfusion reaction (DHTR), 
transfusion associated graft-versus-host disease (TA-GVHD), and post transfusion 
purpura (PTP) (Gresens et al., 2001). 
 
FNHTR and urticarial reaction are the most frequent non life-threatening acute 
transfusion reactions; however, AHTR is the most frequent severe reaction and the 
leading cause of death associated with transfusion. On the other hand, TRALI and 
TA-GVHD are rare and the most fatal transfusion reactions. The case fatality rate is 
5% to 14% for TRALI and over 90% for TA-GVHD. TRALI has been recognized as 
the third leading cause of death associated with transfusion. (Kopko et al., 2001). 
 
ABO incompatibility accounts for about 80% of AHTR-related deaths and occurs as a 
result of error. Well recognized errors include patient misidentification, sample error, 
wrong blood issued, transcription error, administration error, and technical error and 
storage error. Identification and prevention of these errors have become an 
increasingly important issue in transfusion safety. 
 
In general, non immune mediated transfusion reactions result in minor clinical 
manifestations. These include hemoglobinuria, hyperkalemia, hypocalcemia, 
hypothermia, and iron overload. However, air embolus and circulatory overload may 
also be life threatening. Again, these reactions are mostly error related and can usually 
be prevented by proper preparation and storage of components, and better transfusion 
practices. 
 
Despite the risks associated with transfusion, the Canadian blood supply is one of the 
safest blood systems in the world. Effective strategies and laboratory test procedures 
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are being implemented to further prevent and/or reduce transfusion-related adverse 
events. 
Table 2 
Classification of transfusion-related adverse events 
Time of 
Occurrence 
 Mechanism Infectious Reaction Noninfectious Reaction 
Acute Immune 
mediated 
 -- Acute hemolytic 
transfusion reaction 
Transfusion-related acute 
lung injury 
Febrile nonhemolytic 
transfusion reaction 
Urticarial reaction 
Anaphylactic 
Non immune 
mediated 
Bacterial contamination Nonimmune hemolysis 
(e.g. hemoglobinuria) 
Circulatory overload 
Metabolic (e.g. 
hyperkalemia) 
Embolic 
Delayed Immune 
mediated 
-- Delayed hemolytic 
transfusion reaction 
Transfusion associated 
graft-versus-host disease 
Post transfusion purpura 
Non - immune 
mediated 
Transfusion Transmitted 
infections (viral, 
bacterial and parasitic) 
Hemochromatosis (iron 
overload) 
Acute adverse event is defined as any unfavorable event occurring in a patient during 
or within 24 hours after transfusion, but the definition has minor variations in the 
literature. 
 
Delayed adverse event is defined as any unfavorable event occurring in a patient more 
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than 24 hours and up to 3 months after transfusion, but the definition has minor 
variations in the literature 
 
Infectious complications in detail 
There are many Blood borne, transfusion transmitted and related diseases. In the 
United States, many are openly and commonly written about in the press, and spoken 
of on the news.. Some are not. Following here is a partial and growing list of the most 
commonly known Blood transfusion transmitted diseases, but for which no routine 
cost-effective laboratory testing is available. 
 
Hepatitis B 
Despite the dramatic reduction in risk of viral transmission during the past three 
decades, viral hepatitis remains a serious complication of transfusion worldwide 
 
The discovery in 1968 that the viremic phase of serum hepatitis could be recognized 
serologically (Blumberg et al., 1968) sparked the hope that all infectious donors could 
be identified. However, HBV remains a major human pathogen that causes acute and 
chronic hepatitis, cirrhosis and hepatocellular carcinoma (Ganem and Prince, 2004).  
Hepatitis B surface antigen (HBsAg, formerly Australia antigen) is unassembled viral 
coat. Electron microscopy of concentrated serum containing HBsAg revels the 
presence of so-called Dane particles, diameter 42nm, which are known to be complete 
virus (Dane et al., 1970).The particles are made up of an inner protein core (HBc) 
containing partially double stranded DNA with a single stranded region of variable 
length, protein kinase and DNA polymerase surrounded by an outer coat of HBsAg. 
Antibodies to the surface antigen and the core antigen are known respectively as anti- 
HBsAg and anti-HBc.    
Hepatitis B virus (HBV) is transmitted through parenteral and sexual exposure. 
Parenteral transmission is by transfusion of infected blood plasma or coagulation 
factor concentrate and by a variety of other percutanious exposures. Carriers with 
HBsAg below the detection level can transmit HBV by blood transfusion. Patients 
who were seronegative for all seronegative markers, but HBV –DNA by PCR, 
transmitted hepatitis B to two chimpanzees (Thiers et al.,1988). The mean incubation 
time is 90 days with a range of 30 to 180 days. Donor Blood is routinely tested for 
HBsAg and HBcAb. Nevertheless cases in which HBV is transmitted by HBsAg and 
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anti HBc negative donations still occur (Allain, 2004). Washing of red cells reduces 
the viral load and can render units seronegative. However, washing does not eliminate 
the risk of transmission of HBV. Red cells from blood that is only lightly 
contaminated with HBV and is washed, or frozen with glycerol and washed, although 
apparently HBsAg negative, can still transmit HBV to chimpanzees (Alter et al., 
1978a) and humans (Rinker and Galambos  1981). 
 
Screening for HBsAg in blood was initially done by immunodiffusion and 
counterimmunoelectrophoresis. These methods were soon replaced by more 
sophisticated immunoradiometric assay (RIA) and the ELISA, which detect less than 
0.5 ng of HBsAg/ml of blood. However, taking the molecular weight of HBsAg as 
3×10
6
, 0.5 ng is equivalent to 1×10
7
 particles. Thus with a negative result of these 
tests, as many as 4-10×10
7
 antigen molecules may be present per milliliter. Complete 
prevention of post-transfusion hepatitis cannot be achieved by screening for HBsAg. 
Persons who have received a hepatitis B vaccination (recommended for all health care 
workers with patient contact) will have hepatitis B surface antibody present, but not 
HBsAg or HBcAb. Risk of transmission in the Unites States is said to be 1 in 66,000.  
 
Hepatitis-D 
Recipients of Blood products can also be infected with hepatitis delta virus (HDV), 
which is a defective RNA virus that needs an HBV super infection to replicate 
(Tiollais, 1988). The structure and replication of HDV are well described at molecular 
level (Taylor, 2003). Fewer than 10% of carriers of HBV are co-infected with HDV 
and the agent appears to be disappearing (Gaeta et al., 2003). HDV multiplies in the 
liver and is transmitted by blood and body fluids. 
 
Superinfection of a carrier of HBsAg with HDV is associated with a chronic course of 
the delta infection in 70-90 % of cases with an increase in severity of the underlying 
chronic hepatitis (Monjardino and Saldanha, 1990). In HDV infection the delta 
antigen is present in liver and serum. Chronic HDV infection depends on the 
persistence of HBV.  
 
Screening for HBsAg in blood donors minimizes but does not abolish the risk of PTH 
delta in HBsAg positive recipient (Rosina et al., 1985). The simultaneous presence of 
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HDV and HBeAg in the absence of detectable HBsAg has been reported (Shattok et 
al., 1985). HDV has been transmitted not only by blood and blood components, but 
also by coagulation factor concentrates (Purcell et al., 1985). 
 
Hepatitis C 
After the introduction of routine screening of blood donations for HBsAg, the great 
majority of cases of post transfusion hepatitis is due to hepatitis C virus, a flavivirus. 
(Alter et al., 1989a). Blood components and blood products including anti-D Ig 
transmit HCV. For intravenous use (Yap et al., 1993) and factor viii concentrate 
submitted to some of the virus inactivation procedures (Bergman, 1995). The hepatitis 
C virus (HCV) currently affects over four million people in the United States. This 
disease has reached epidemic proportions. It is the primary reason for liver 
transplantation in the United States hepatitis C virus (HCV) infection is still the most 
common transfusion transmitted infection. Persons at highest risk for the virus are 
those who received blood transfusions prior to 1991 or people with a history of IV 
drug abuse using shared needles. One attribute of this disease that contributes to the 
high rate of infection is that the time from infection with the virus until manifestation 
of liver disease can be decades. The hepatitis C virus subtype varies worldwide. In 
Europe, types 1, 2 and 3 are the predominant genotypes with types 1a and 3a in the 
northwestern countries and 1b in Hungary, Germany, Russia and Turkey. In North 
America, types 1a and 1b have been found. In Japan and Taiwan, types 1b, 2a and 2b 
predominate; type 6a in Hong Kong and Macau. Type 4 is found in Zaire, Central and 
North Africa; 5a in South Africa. The hepatitis C virus is taken into the body other 
than through the digestive tract. It must be inherited, transfused or injected in some 
manner. The sexual transmission rate is lower than once thought. At present, only 
testing for hepatitis C antibody is available. The antibody to the hepatitis C virus 
appears 54 to 192 days in a person's Blood after infection. If an infected person 
donates Blood prior to the appearance of this antibody the chance of that Blood being 
used in a transfusion is said to be one out of 103,000 donations, There are an 
estimated 15-million Blood transfusions each year. Risk of transmission in the Unites 
States is said to be 1 in 121,000.  
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Hepatitis E 
Hepatitis E virus (HEV) is a non-enveloped RNA virus responsible for epidemic 
hepatitis in Asia, Africa, Latin America and the Middle East and sporadic hepatitis in 
developed countries. HEV is nearly always transmitted by faecal-oral route. However 
– like HAV transient viraemia develops after infection and transmission by blood 
transfusion does occur (Matsubayashi et al., 2004) 
GB Virus (GBV / HGV) 
Blind molecular cloning, similar to the strategy used to discover HCV, has resulted in 
the detection of several other transfusion- transmitted viruses. Using amplification 
techniques, cloning and sequencing, at first two viruses GBV-A and GBV-B found 
only in tamarins, and later a third virus, GBV-C, from a human serum were identified 
(Simons et al., 1995; Yoshiba et al., 1995). Of the three ‘GB viruses GBV-C is the 
only human virus. GBV-C has been recovered from the blood of several patients with 
hepatitis, from multitranfused patients, hemophiliacs and intravenous drug users. The 
GB viruses are flavivirus – like agents similar to HCV, with a similar genomic 
organization. In relatively small studies, the prevalence of GBV-C has been found to 
be quite high; two percent in blood donors in the USA and the UK and twelve to 
fourteen percent in multiply transfused patients (Denis et al., 1996). GBV-C has been 
detected in three out of six patients with fulminant non-A, -B, -C or –E hepatitis but 
the real significance of the virus as a cause of hepatitis, PTH and chronic lever disease 
has still to be established (Yoshiba et al., 1995)  
 
Human Immunodeficiency Virus (HIV) 
Although retroviruses were among the first known viruses, for almost a century they 
were only found in animals, usually in association with neoplastic diseases. Until 
1980, retroviruses had not been linked to human disease, let alone to transfusion-
transmitted infection. However, the sensitive immunological, biochemical molecular 
approaches that became available in the 1970s led to the discovery of the first human 
retroviruses, isolated from lymphocytes of a patient with T-cell leukemia. And 
appropriately named human T- lymphotrophic virus type-1 (Poiesz et al., 1980). 
Knowledge of the existence of prototype retroviruses encouraged a search for a 
human retrovirus as the etiological agent of AIDS. The causative agent originally 
referred to as LAV or HTLV III and now called human Immunodeficiency virus 
(HIV) was discovered in 1983 (Barre-Sinoussi  et al., 1983). They are RNA viruses, 
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which after entering host cells and losing their envelope, use ‘reverse transcriptase’ 
(RNA dependent DNA polymerase) together with cell derived RNA as a primer to 
transcribe a double stranded DNA copy of the single stranded viral RNA genome. All 
retroviruses contain three main structural genes; the gag gene codes for different 
molecular weight proteins that are integral to the nuclear core, the pol gene codes for 
reverse transcriptase; and the ena gene specifies for the envelope glycoprotein. The 
integrity of the envelope is essential for infectivity. The high lipid content of the 
retroviral envelope renders these agents very susceptible to disruption by detergents 
and organic solvents. All human retroviruses code for a small conservative major core 
protein, p24, and have similar modes of transmission, i.e. sexual, congenital and by 
blood or body fluids. (Wong-Staal and Gallow, 1985). Human retroviruses all share a 
tropism for lymphocytes inducing fusion and giant cell formation in vitro and 
impairing function in vivo. The high affinity receptor for HIV has been identified as 
CD4 on helper T-lymphocytes, macrophages and other cells. 
 
HIV I and HIV II:  In 1982 the first cases of AIDS transmitted from Blood or Blood 
components were reported, but little of the infection was known at that time, and even 
less was talked about publicly. The causative agent of AIDS was originally described 
as LAV (lymphadenopathy virus) (Vilmer et al., 1984). Gallow and his colleagues 
succeeded in culturing the same virus, which they called HTLV III in large quantities 
in continuously replicating T cells (Popovic et al., 1984). This virus, along with visna 
virus, belongs to the lentivirus subfamily of retroviruses. HIV was found to induce 
premature death of its host cells and to replicate rapidly (Gallow et al., 1984) 
 
A second distinct retrovirus named HIV II causes a somewhat milder disease. 
Although this is also lymphotropic, cytotoxic and neurotropic, and shares epitomes of 
the core and pol proteins with HIV-I HIV-II nucleotide sequence identity with HIV I 
isolates is only 40-50%. The main difference between HIV II and I lie within the 
envelope nucleotides and proteins. The HIV I envelop glycoprotein gp120 binds 
specifically to CD4-bearing cells and interact with gp41 for virus-cell and cell-cell 
fusion events (Dalgleish et al., 1984). Two to four months after sexually transmitted 
infection, and 1-2 months after transfusion- transmitted infection, more than 95% of 
HIV-infected subjects exhibit a wide range of antibodies to the structural viral 
proteins. Disease develops when the CD4 helper cells have almost completely 
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disappeared, leading to impairment of the immune system and spread of HIV with 
signs of disease in multiple organs; anti-p24 declines and p24 antigen reappears at this 
stage. 
Transmission of HIV infection and spread of AIDS by blood transfusion 
Recognition of a possible relationship between blood transfusion and the acquired 
immune deficiency syndrome (AIDS) provided early clues that AIDS might have an 
infectious cause. In July 1982, three patients with severe classic hemophilia who 
developed Pneumocystis carini pneumonia were reported by the Centers for Disease 
Control in the morbidity and mortality Weekly Report (MMWR and CDC, 1982). All 
had been treated with large doses of commercially prepared factor VIII concentrate. 
Because HIV is both cell associated and present in plasma, all blood components are 
potentially infectious (Curran et al., 1985). The virus is well preserved in refrigerated 
and frozen blood; however, components that are washed, leucoreduced or cold stored 
for several weeks, reduce the likelihood of transfusion transmission (Donegan et al., 
1990a). 
 
In much of Asia and Africa the transmission of HIV by blood transfusion is still an 
important source of infection. Reasons for an alarmingly high rate of transmission, 
reported to be up to 10% of all cases, include 
 
1. The demand for blood for patients with severe anemia and hemorrhage, mainly in 
obstetrics, gynecology and pediatrics; 2. The prevalence of HIV infection amongst the 
donor population. 3. The fact that HIV infection is not confined to a minority of the 
population who can be requested to refrain from blood donation; and 4. The inability 
of many laboratories to test for HIV or to perform and control the tests properly. 
 By 1983 radical changes began to occur in the donor criteria to exclude those at high 
risk for transmission of HIV. The testing of blood products for HIV started in 1985. It 
was a test to detect the presence of the antibody directed against HIV, rather than a 
direct test for HIV. Testing for HIV p24 antigen was mandated in 1996 in USA. Risk 
of transmission in the Unites States is said to be 1 in 563,000. Infections in persons 
Infected with HIV. However, in countries with a high percentage of infected subjects 
and where HIV is spread mainly by heterosexual intercourse, the risk of transmission 
of HIV by blood transfusion is still considerable.  
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Human T-lymphocytotrophic Virus (HTLV-1) 
The human T-cell lymphocytotrophic virus Type-1 (HTLV-1), the first human 
retrovirus to be described, was isolated from cultured cells from a patient with an 
aggressive variant of mycosis fungoides and from a patient with Sezary syndrome 
(Poiesz et al., 1980). HTLV-1 is the causative agent of adult T-cell leukemia. The 
virus is also associated with lung infections, cancer of other organs, monoclonal 
gammopathy and renal failure and other opportunistic infections. These effects may 
be due to the immunodeficiency induced by HTLV-1 infection (Takatsuki, 1996).  
 
HTLV-1 and –II belong to the oncovirus sub type of the retrovirus family and are able 
to induce polyclonal proliferation of T lymphocytes in vitro and in vivo.   
 
This is a retrovirus that is endemic in Japan, with prevalence as high as 15% (Maeda 
et al., 1984) and in the Caribbean with 1-8% prevalence (Clark et al., 1985), in 
regions of Central and South America and in parts of sub-Saharan Africa (Gessain et 
al., 1986; Vrielink and Reesink,  2004). 
 
HTLV-2 the second human retrovirus to be discovered, has a 65% nucleotide 
sequence identity with HTLV-1 and a significant serological cross reactivity (Hjelle., 
1991).  
 
HTLV-1 has been transmitted by cellular components, but not by cell-free plasma or 
plasma derivatives (Okochi, 1985). However, HTLV-RNA is detectable in plasma 
from infected subjects. Recipients of HTLV-1 infected concentrates may develop 
HAM (Araujo and Hall, 2004). ATL developed in two immuno-suppressed patients 
who had received multiple transfusions six and eleven year earlier (Chen et al., 1989).  
 
HTLV-2 has also been transmitted by blood transfusion (Hjelle et al., 1990b).    
Blood is routinely screened for antibodies to HTLV-1 utilizing this relatively 
inexpensive test. Risk of transmission in the United States at this time is said to be 1 
in 641,000.  
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Transfusion Transmitted Virus 
Transfusion Transmitted Virus is a relatively new virus becoming widely known in 
1997 in patients with fulminant hepatitis and chronic liver disease of unknown 
etiology. TTV is an unenveloped, single stranded DNA virus. Two genetic groups 
have been identified, differing by 30% in nucleotide sequences. TTV DNA was 
detected in 47% of patients with fulminant non-A-G hepatitis and 46% of patients 
with chronic liver diseases of unknown etiology. The result suggests that TTV may be 
the cause of some cryptogenic liver diseases. In testing, the presence of TTV was 
found in approximately 10% of U. S. volunteer Blood donors, 13% of commercial 
Blood donors, and 17% of intravenous drug abusers. The rate of TTV infection 
among U. S. non-A, non-B, non-C, non-D, non-E hepatitis patients was only 2%.  
 
Cytomegalovirus (CMV) 
The prevalence of the CMV antibody ranges from 50% to 80% of the population. 
Blood contaminated with CMV can cause problems in neonates or 
immunocompromised patients. Potential problems in selected patient populations can 
be prevented by transfusing CMV negative Blood or frozen, deglycerolized RBC's. 
Donor Blood is not routinely tested for CMV. 
 
Cytomegalovirus (CMV) is a large, enveloped, double stranded DNA, beta herpes 
virus that is cell associated, but may also be found free in plasma and other body 
fluids (Drew et al., 2003). CMV has a direct cytopathic effect on infected cells. The 
result may lead to neutropenia, some depression of cellular immunity and inversion of 
T-cell subset ratios, with a consequent increase in susceptibility to bacterial, fungal 
and protozoa infection in immunosuppressed patients (Grumet, 1984; Landolfo et al., 
2003).  CMV infection causes parenchymal damage, such as retinitis, pneumonitis, 
gastroenteritis, encephalitis, and can result in substantial morbidity and mortality. 
 
The frequency of subjects with anti-CMV varies widely in different populations. 
Seroprevalence is lower (30-80%) in developed than in developing countries, where 
the figure may reach 100% (Krech, 1973; Preiksaitis, 1991). The prevalence of anti-
CMV correlates with age and socioeconomic status (Lamberson, 1985; Tegtmeier, 
1986). 
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The transmission of CMV by blood transfusion was first reported in the 1960s 
(Kaariainen et al., 1966; Klemola et al., 1969). CMV is now known as one of the 
infectious agents most frequently transmitted by transfusion. The pathogenesis of 
transfusion-transmitted CMV infection is not clearly understood. Primary infection 
rates depend on the number of transfusions, age of blood, and time of year and 
immunocompetence of the recipient (Tegtmeier, 1989; Preiksaitis et al., 1988; 
Preiksaitis, 2000). At present, no rapid, easy way to identify infectious subjects exists. 
Before an era of universal (or near universal) leucoreduction, 30% of anti-CMV-
negative recipients undergoing cardiac surgery involving transfusion developed 
infection. Of patients who develop a primary or recurrent CMV infection following 
transfusion, fewer than 10% developed mononucleosis – like syndrome after three to 
six weeks of transfusion (Foster, 1966). 
 
During the past decade, major advances have been achieved regarding the 
management of CMV (Meijer et al., 2003). Nevertheless, in immunosupressed 
patients, or in fetuses and premature infants CMV infections still cause severe disease 
that can be fatal.    
 
Subjects infected with HIV and especially those with AIDS, if anti-CMV is negative, 
may acquire primary CMV infection by transfusion (Sayers et al., 1992). 
 
Window period infections are the most likely source of antibody screening failures. 
Although the window periods for HIV-1, HCV and HBV have been reasonably well 
defined, the length of the CMV-seronegative window, estimated 6-8 weeks, is less 
well characterized (Zanghellini et al., 1999). 
 
Epstein-Barr Virus 
Infection with Epstein-Barr virus (EBV), a herpes virus – like CMV, is endemic 
throughout the world. EBV can cause primary symptomatic infection (infectious 
mononucleosis), but most commonly causes asymptomatic infection followed by 
latent infection (Henle, 1985).  
 
Post transfusion infectious mononucleosis is seen only rarely in anti-EBV-negative 
immunocompetent patients and usually occurs only when a single unit of blood or 
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blood component, obtained from the donor during the incubation phase is given 
within 4 days of collection. 
 
Other Herpes Viruses  
Human herpes virus-6 (HHV-6) is a recently characterized virus, originally named 
HBLV (human B lymphotropic virus) for its ability to infect freshly isolated B cells. 
The virus was found in patients with various lymphoproliferative disorders. HHV-6 
can infect monocytes, macrophages, T cells megalkaryocytes (Ablashi et al., 
1987).The virus was found to be ubiquitous in blood donors when tested in London 
and the USA (Briggs et al., 1988). No transfusion-associated disease has been 
reported. 
 
HHV-8, Kaposi’s sarcoma virus is white cell associated and may be present in up to 
30% of normal donors. Despite a relatively high HHV-8 seroprevalence in a Texas 
blood donor cohort (23%), HHV-8 DNA was not detected in any sample of donor 
whole blood using a highly sensitive PCR assay (Hudnall et al., 2003). 
 
Human parvovirus B19 
HPV B19 was discovered by an Austalian virologist in an assay for hepatitis B 
(Cossart et al., 1975). HPV B19 is a small single-stranded, non-enveloped, 
thermostable DNA member of the parvoviridae family (Young and Brown, 2004). 
The parvoviruses are dependent on help from host cells or other viruses to replicate. 
The red cell P antigen, a globoside present on a variety of cells in addition to 
erythrocytes, has been documented as the specific receptor for HPV (Brown et al., 
1994). 
 
Transmission of HPV by blood transfusion – HPV B19 has been transmitted by 
plasma fractionation products derived from large pool of plasma, particularly by 
factor VIII and factor IX concentrates (Blumel et al., 2002). Transmission of virus by 
single- donor components is unusual, but red cell unit has been associated with HPV 
B19 transmission and possible cardiac involvement in 22 years old women with 
thalassaemia major (Zanella et al., 1995). 
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West Nile Virus  
West Nile Virus is a mosquito –borne flavivirus transmitted primarily to birds and 
some small mammals. Humans serve as an incidental host. Approximately 80%of 
human infections are assymptomatic, 20% result in a febrile illness known as West 
Nile Fever. About 1in 150 patients develop meningoencephalitis and residual 
neurological deficits have been reported. The period of infectivity has not been well 
defined. Of the 23 well-studied patients with transfusion transmitted infection, 14 
were identified. The illness began between 2 and 21 days after the implicated 
transfusion. Red cells, platelets and fresh-frozen plasma (FFP) have all been 
implicated in transmissions. Six cases of WNV transmitted by transfusion occurred 
because of transfusion of components containing low levels of virus not detected by 
the testing of pooled specimens (Macedo et al., 2004). Other flaviviruses such as St 
Louis encephalitis virus, Japanese encephalitis virus and dengue virus are likely to be 
blood transmissible as well, although documentation is lacking.  
 
Simian foamy virus  
Simian foamy virus (SFV) (spumaretrovirus) is a highly prevalent retrovirus that has 
been shown to infect human cells. Tropisim is broad and includes B and T 
lymphocytes, macrophages, fibroblasts, endothelial cells and kidney cells. Persistent 
viremia has been detected in peripheral blood lymphocytes. (Boneva et al., 2002) 
Evidence of SFV infection included seropositivity, proviral DNA detection and 
isolation of the virus. There is no evidence as yet that SFV causes human disease but, 
recombination within the host, especially in immunocompromised hosts that may 
allow persistent infection, remains a concern. 
 
Creutzfeldt-Jakob Disease (CJD) 
A degenerative and fatal nervous system disorder. Affected individuals can remain 
asymptomatic for decades after infection and then progress rapidly to dementia, 
severe loss of coordination and death. The risk of CJD being transmitted through 
Blood products is ‘theoretical.’ However, all Blood banking organizations in Europe, 
and now in the United States, prohibit Blood donation by individuals who have 
symptoms or a family history of symptoms. 
Unlike classic CJD, vCJD usually affects younger subjects (age 18-53 years) and is 
characterized by early psychiatric and sensory symptoms. 
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Prion protein has been identified on a wide range of circulating cells including 
platelets, myeloid cells, lymphocytes and red cells (Dodelet and Cashman, 1998; 
Holada and Vostal, 2000; Bessos et al., 2001; Li et al., 2001). Findings in 
experimental models show that blood not only contains infective agents of prion 
diseases, but that no barrier to transmission exists with intraspecies transmission and 
that the intravenous route of exposure to prions is fairly efficient (Casaccia et al., 
1989; Cervenakova et al., 2003). In 2004, the first probable transfusion associated 
case of vCJD was described (Llewelyn et al., 2004).  
 
Transmissible Spongiform Encephalopathy (TSE) agents are resistant to a range of 
physical and chemical means that have been used to inactivate viruses in plasma 
products. However, processes used to purify proteins, including factor concentrates 
can contribute significantly to removing both abnormal prions and infectivity (Lee et 
al., 2001). 
 
Blood donors are carefully questioned about family history of CJD and surgeries that 
involved transplanted dura mater. If they answer affirmatively to any of these 
questions, they are permanently deferred as a donor. We see here again the potential 
danger in the 'honor system' of Blood donation in the United States. There is no 
possibility of contracting CJD by making a normal Blood donation.  
 
Leishmaniasis 
Cases of transfusion-associated Leishmaniasis are growing each year world wide. 
This increase is increasingly associated with patients who are positive for HIV. 
Transfusion-associated Leishmaniasis requires that the parasites be present in the 
peripheral Blood of the donor, survive processing and storage in the Blood bank, and 
infect the recipient. L.tropica has been demonstrated to survive in stored blood under 
blood bank conditions for 25 days (Grogl et al., 1993). In endemic areas where the 
population of potentially infected individuals may be much higher and the screening 
process for donors less rigorous, transfusion-associated Leishmaniasis is more 
common. Leishmaniasis is now found in over 90 countries. Again here we see the fact 
of world travel by a diverse population, and the 'honor system' Blood donor screening 
process, and too expensive testing, all contribute to the increase of transfusion 
transmitted Leishmaniasis.  
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Malaria  
The popular statement, routinely given is that "malaria is rarely transmitted by Blood 
products." The number of transfusion associated cases of malaria, however, is at an 
all-time high. Malaria can be transmitted by the transfusion of any blood component 
likely to contain even small numbers of red blood cells; platelet and granulocyte 
concentrates, fresh plasma and cryoprecipitate have all been incriminated. An 
inoculum containing as few as 10 parasites can cause Plasmodium vivex malaria 
(Bruce-Chwatt, 1972).  
 
Malaria parasites of all the species can remain viable in stored blood for at list 1 week 
(Hutton and Shute 1939) Malaria is particularly serious in pregnant women and in 
spleenactomised or immunosuppressed patients (Bruce-Chwart, 1985). 
There are no practical laboratory tests available to test donor blood, so donors 
traveling to high risk malaria areas are often deferred from donating blood for six 
months.  
 
Chagas Disease 
Discovered a century ago by Brazilian doctor Carlos Chagas, this disease, properly 
named Chagas' Disease, is caused by a parasite that infects an estimated 18 million 
people worldwide, causing death from heart and digestive problems. Up to 20% of 
infected people never exhibit symptoms. Because of recent shifts in population, 
individuals from countries where this disease is common (South and Central America) 
are migrating in large numbers to the United States and other countries.  
 
Babesiosis 
An intraerythrocytic parasitic infection caused from the bite of the infected Ixodes 
tick. The disease closely resembles in some ways Lyme Disease, and in other ways, 
malaria. This significantly affects the hematological system, causing among other 
things, hemolytic anemia, thrombocytopenia, and atypical lymphocyte formation. The 
transmitted parasite only infects red blood cells by altering the cell membranes that 
causes decreased conformability and increased red cell adherence, which, in turn, can 
lead to development of acute respiratory distress syndrome (ARDS) among those 
severely affected. Babesia parasites invade and survive within erythrocytes. These 
blood-borne parasites remain viable under blood bank conditions. In Europe, 
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Babesiosis is a life-threatening disease and is a significant public health problem in 
regions of the northeastern United States. Of patients with Babesiosis, 84% are 
asplenic, and 53% become comatose and die. Those individuals with a history of the 
disease are to be permanently deferred from donating blood, if they know and admit 
before blood donation that they have carried the malady.  
 
Toxoplasmosis  
 A systemic protozoan infection that causes symptoms similar to infectious 
mononucleosis. In immunocompromised individuals this infection can have serious 
neurological symptoms and can cause fetal death in pregnant women. Toxoplasmosis 
is also transmitted by common house cats.  
 
Bacterial Contamination of Blood Products  
This is another less often observed risk disorder directly associated with blood 
transfusion. It is increasingly rare but a very serious complication of blood 
transfusion. Most commonly associated with contamination during blood collection or 
during handling of blood products, such as preparation of platelet pools, and on 
occasion, associated with bacterial infection of the donor, it is sometimes 
recognizable by obvious changes in the appearance of the blood product. Studies 
indicate that the rate of contamination of blood products by bacterial pathogens may 
be significant. Since blood recipient death continues to occur, in 1997, the CDC 
entered into an agreement with national Blood collection and distribution agencies to 
determine the frequency of transfusion reactions associated with bacterial 
contamination of blood products. The new study will be a critical step in addressing 
this issue and will increase clinicians' awareness of bacterial contamination as a cause 
of transfusion reactions. Currently, the nation's blood supply is not screened for 
bacterial contamination. Amazingly, when this contamination issue is raised, blood 
donor deferral is merely recommended, and not mandatory. 
 
Some common transfusion transmitted bacterial infections are as follows… 
Treponema pallidum  
Treponema pallidum is a motile spirochaete that spreads by sexual contacts, 
transfusion, percutaneous exposure and transmission from mother to infant. The 
incubation period from transfusion to clinical presentation varies from 4-weeks to 4.5 
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months,averiging 9-10 weeks. Donors at any stage of the disease,including late,latent 
syphilis, can transmit infection (Hartmann and Schone, 1942). Transfusion-
transmitted syphilis was once considered a serious problem. Some 138cases had been 
reported by 1941 (De Schryver and Meheus, 1990). Since then, few cases have been 
reported in the developed world. The chief reasons for the decline of transfusion –
transmitted syphilis seem to be almost universal practice of storing blood at 4degree C 
before transfusion, universal donor testing and the decline in the prevelance of 
syphilis in many countries. Spirochaetes are unlikely to survive in citrated blood 
stored for more than 72 hours at 4-6degree C (Bloch, 1941). Serological tests cannot 
prevent all cases of transfusion syphilis because most remain negative in early 
primary syphilis, when spirochaetaemia is most prominent (Spangler et al., 1964). 
The rational for continued syphilis testing relies upon the increasing demands for 
fresh blood components,specially platelets and fresh blood for exchange transfusion 
in new born infants. (Risseeuw-Appel and Kothe, 1983) and its questionable value as 
a surrogate test to exclude donors who are in high-risk groups for HIV and HBV 
infection. 
 
Brucella abortus 
This organism can survive for months in stored blood and ther are several reports of 
blood transfusion-transmitted symptomatic infection, mainly in children and 
splenectomizwd patients (Wood, 1955; Tabor, 1982). After an incubation period 
ranging from 6 days to 4 months, recipients of infected blood may develop undulant 
fever, headache, chills, exessive sweating, muscle pains and fatigue. 
Hepatosplenomegaly, lymphadenopathy, leucopenia and arthritis occur and vary 
rarely, complications such as purpura, encephalitis or endocarditis develop (Tabor, 
1982). 
 
Lyme Disease 
The organism responsible for this disease is Borrelia purgdorferi, a spirochaete. 
Lyme disease is associated with the bite of the eastern deer tick, and can cause an 
illness that affects many systems within the body. 
 
Although no cases of transmission of B. burgdorferi by blood transfusion has been 
reported so far, transmission is theoretically possible. The spirocheate has been 
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isolated from blood as old as 14 days. Donors with a history of Lyme disease can not 
donate Blood unless they no longer have symptoms whatever, have undergone a full 
course of antibiotic treatment, and are cleared by a physician. Public health and Blood 
agencies are closely monitoring this disease. 
 
Exogenous and various endogenous bacteria and bacterial products 
contaminating stored blood or blood components 
1. Bacteria may contaminate solutions or equipments to be used for transfusions but 
which have not yet been sterilized. After sterilization the solutions or equipments may 
remain contaminated with heat-stable bacterial products (pyrogenes). In contaminated 
solutions or equipments such as hydroxyethyl starch used for leucapheresis, bacteria 
may survive ‘sterilization’ or may contaminate solutions that have previously been 
sterilized, for example when a glass container is cracked during shipment (Wang et 
al., 2000). 
2. Bacteria originating from skin flora, such as Staphylococcus epidermis, 
Micrococcus species, Sarcina species and diptheroids, may gain entrance during 
venesection. (Anderson et al., 1986). 
3. Bacteria in the environment (Pseudomonas species, Flavobacterium species and 
Bacillus species) may gain entrance to blood components through minute lesions in 
the packs, during collection or processing in open systems (Szewzyk et al., 1993). 
4. Bacteria circulating in the blood of an apparently healthy donor suffering from 
asymptomatic bacteremia may proliferate in red cell components stored at 4ºC or in 
platelet concentrates stored at room temperature. 
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CHAPTER 3  
MATERIALS AND METHODS 
 
Study Group 
We selected four groups of patients undergoing multiple blood transfusions. Groups 
are as follows. 
1. A group of 130 thalassemic patients at K.T. Children Hospital, Rajkot initially 
included in the study in the year of 2003. At the end of the study we had  
registered 218 patients. These patients had been receiving blood transfusions 
regularly at K.T. Children Hospital since 2003 till the end of the study period. 
Patients who had received at least 2 previous blood transfusions were included for 
serological follow up for 5 successive years (2003, 2004, 2005, 2006 and 2007). 
Transfusion and clinical records of all patients were maintained. About 3 ml blood 
sample was collected and samples were preserved. 
Analysis of 121 patients was done at the end of the study and the others were 
excluded due to various reasons (05 patients moved, sample was inadequate in 02, 
one patient died and one was lost to follow up).  
2. At Hemophilia Society, Rajkot a group of 156 hemophilic patients were registered 
initially in the study, at the end of the study in 2008 we have registered 232 
hemophilic patients. Transfusion and clinical records of all patients were 
maintained throughout the study. 
3. A group of 115 CRF patients at B. T. Savani Kidney Hospital, Rajkot undergoing 
hemodialysis were registered in 2003; at the end of the study in 2008 we 
registered 220 patients. We have recorded all the details of the patients like age, 
sex, prior H/O transfusion, frequency of dialysis etc. 
4. We selected a group of patients from a multi speciality hospital who went for 
surgical procedure or any procedure that led them to multiple blood transfusions. 
Number of patients registered in 2003 was 58 and at the end of the study in 2008 
the count was 61. We have recorded all the clinical history and transfusion records 
of all patients. 
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5. We selected a small group of Leukemic patients who went on multiple blood 
transfusions. We registered 10 patients for our study and we have recorded all 
clinical and transfusion history of all patients. 
 
Serological study 
Frozen samples were tested after the study period for various viral markers in the 
same laboratory by one person using the same batches of reagents and kits. Tests were 
carried out by commercially available, third generation, enzyme linked 
immunosorbent assay (ELISA) for the following TTD markers: (i) HBsAg 
(Microscreen HbsAg ELISA Test Kit by Span Diagnostics) (ii) antibodies to HCV 
(SP- NANBASE C-96 3.0 test kit by General Biological Corp.); (iv) anti HIV I/II 
(Enzaids HIV 1+2 ELISA test kit by Span Diagnostics); and (v) antibodies to CMV 
(IgM) (Equipar diagnostic kit.). Tests could not be repeated due to lack of serum 
samples and in some cases because of high reagent cost. We have done hematological 
studies of all samples like blood indices as well as bacteriological studies like culture 
of samples. 
 
Screening for HIV  
Introduction 
Test was done by Enzaids HIV 1+2 ELISA test kit by Span Diagnostics. 
AIDS is caused by Human Immunodeficiency Viruses viz. HIV Type-1 and HIV 
Type-2, as the etiological agents (Schupbach et al., 1984; Gallow et al., 1984) The 
serological analysis of the viruses, collectively referred to as HIV 1+2, laid the 
foundation of an ELISA based assay system for the qualitative detection of 
antibodies, in the human serum or plasma, indicating an exposure to the virus. 
 
Conventionally used viral lysate proteins or their constituent polypeptides are now 
substituted by similar synthetic and/or recombinant (non-infectious) antigens 
(Schneider et al., 1987). Enzaids, with the use of these antigens, ensures highest level 
of specificity and sensitivity of the detection system. 
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Principle 
The antigenic peptides/ proteins are adsorbed onto the wells of a microplate. These 
antigens are selected from immunodominant regions of HIV-1 and HIV-2, so as to 
provide maximum level of sensitivity. Special sample diluents is developed using 
proprietary formulation to minimize the non-specific binding. Test serum and 
controls, along with sample diluents are added to the respective wells and incubated. 
The conjugate binds to HIV antibodies that are already bound to immobilized 
antigens. A wash step removes the unbound conjugate. The substrate for the enzyme 
peroxidase and the chromogen 3,3’,5,5’ Tetramethylbenzidine (TMB) are added to all 
the wells and incubated further, resulting into a blue colored complex. The reaction is 
terminated by the addition of a stopping solution yielding a stable yellow colored end 
point. The intensity of color is proportional to the concentration of anti HIV-1 and/or 
HIV-2 present in the test specimen or control. 
 
Contents of the Kit 
Reagent: 1 
Sample Diluent: Tris buffer, proteins and preservatives. 
Reagent: 2 
Conjugate: Peroxidase labeled anti-human immunoglobulin containing 
protein stabilizers and 0.01% Thimerosal as preservative. 
Reagent: 3 
Washing Buffer: Concentrated buffer containing Tween-20 and 0.01% 
Thimerosal as a preservative. Before use, dilute by adding one volume of 
concentrate to 9 volumes of distilled water. 
Reagent: 4 
Negative Control: Anti-HIV negative human serum, negative for Anti 
HIV-1 and Anti HIV-2 and containing 0.01% Thimerosal as preservative. 
Reagent: 5 
Positive Control: Inactivated serum containing anti-HIV antibodies and 
0.01% Thimerosal as preservative. 
Reagent: 6  
Color reagent: Buffer containing hydrogen peroxidase and 3, 3’, 5, 5’ 
Tetramethyl benzadine (TMB) in solution. 
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Reagent: 7 
Stopping Solution: Mineral acid. 
Reagent: 8 
Microwell strips: Coated with HIV 1+2 Recombinant and synthetic 
peptides. 
 
Assay Procedure 
 All the reagents were brought to room temperature before use, except color 
reagent. Required number of Microwells/ strips was removed from the packet. 
The wells were labelled appropriately. 
 The reaction Blank well was left empty. 
 200 µl Sample Diluent (Reagent 1) was dispensed to rest of the required wells. 
Three Negative (Reagent 4) and one Positive (Reagent 5) controls in each run 
were used. 10 µl of Negative, Positive and test serum samples to the respective 
wells was added. The strips were mixed properly and covered with adhesive 
strip cover & Incubated for 30 minutes at room temperature (20°C-30°C). 
 The adhesive strip cover was removed and discarded. The contents of the well 
were decanted into a waste container. The wells were filled with diluted 
Washing Buffer & allowed soak time of 30 seconds and then decanted in a 
waste container.  The procedure was repeated for 4 more times. The wells 
were drained on a disposable absorbent pad or towel firmly to remove excess 
of fluid. Care was taken not to scratch the inner surface of well with pipette 
tips or tissue paper. 
 50 µl of Conjugate (Reagent 2) was added to each well, except the one used 
for the Reaction Blank Control. 
 The contents of the Microwells were mixed by agitating the strips gently for 5-
10 seconds. 
 The strip was covered with fresh adhesive strip cover and incubated for 30 
minutes at room temperature (20°C-30°C).  
 Remove and discard the adhesive strip cover. Wash strip as in Step 4, five 
times with diluted Washing Buffer. 
 100 µl of Color Reagent (Reagent 6) was added into each well including 
Reaction Blank Control. 
 It was incubated at room temperature for 15 minutes in dark. 
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 The reaction was stopped by adding 100 µl of Stopping Solution (Reagent 7) 
in all the wells. 
 The contents of Microwells were mixed by agitating the strips gently for 50-10 
seconds. 
 Using bichromatic (450+630 nm) mode, absorbance readings were taken after 
blanking with A1 (Reagent blank) well. 
 
Calculation for Determining Cutoff Value 
Negative Control Mean (NCx) 
Determine the Mean of Negative Control as shown below. 
Example 
Sample no.             Absorbance 
1                     0.064 
2                      0.055 
3                      0.076 
        Total:                           0.195 
NCx = 0.195/3 = 0.065 
Positive Control 
To consider the assay run to be valid, the absorbance value obtained for the Positive 
Control should be at least 1.00. If not, the assay must be repeated making sure that the 
procedure is being properly followed. 
Blank 
The absorbance value (O.D.) of Reagent blank should fall between 0.000 and 0.100 in 
bichromatic mode. 
Cutoff Value 
The cutoff value is the mean O.D. of the Negative Control plus 0.225. 
Example 
NCx = 0.065 
Cutoff Value = 0.065+0.225= 0.290 
 
Interpretation of Results 
All the samples with the absorbance less than cutoff value were considered Negative 
for anti-HIV and the absorbance equal to or more than cutoff value were considered 
Positive for anti-HIV. 
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Non reactive results in a test for detecting antibodies against HIV-1 and/or HIV-2 do 
not exclude HIV infection with absolute certainty, if the patient happens to be in the 
window period (Cordes et al., 1995).  
 
Limitation of the Test 
 A non reactive result with this test does not preclude the possibility of HIV 
infection. 
 Demonstration of the presence of HIV antibodies in test serum has extensive 
serious social implications. Hence, confirmation of a reactive sample by an 
acceptable technique such as a Western Blot test is of vital importance. 
 Test procedure must be followed meticulously. 
     
Screening for HBsAg 
Hepatitis B virus causes Acute Viral Hepatitis, a common yet serious infection. 
HBsAg appears early during the course of infection and normally serves as a marker 
for the primary diagnosis (Blumberg et al., 1965). 
 
Principle of Test 
Microscreen HBsAg is a direct, non-competitive solid phase enzyme immunoassay 
for detection of various subtypes (ad & ay) of HBsAg in Serum or Plasma. 
1. Wells are coated with immobilized HBsAg antibodies in which Test Serum or 
Plasma is added. If HBsAg is presnt in Test Serum or Plasma it will combine 
with HBsAg antibodies coated on wells. This complex further combines with 
peroxidase conjugate of anti-HBsAg antibody. 
2. On additon of Substrate, chromogenic reaction with the enzyme produces a 
coloured end product. 
3. This reaction is then stopped by addition of Mineral Acid and the absorbance 
is measured. 
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Kit components 
Reagent 1 
Sample Diluent: Tris Buffer, Proteins, Preservatives and Detergent. 
Reagent 2 
Conjugate: Monoclonal anti HBsAg antibodies conjugated with Peroxidase 
containing Protein Stabilisers and Preservatives. 
Reagent 3 
Washing Buffer: Concentrated Tris Buffer, containing Tween 20 & 
Thiomersol(0.01%) as Preservative. Before use, dilute by adding one volume 
of concentrate to 9 volumes distilled or Reagent Grade Water (Span product 
no.23668A or equivalent). 
Reagent 4 
Negative Control: HBsAg Negative Human serum, containing Preservative. 
Reagent 5 
Positive Control: HBsAg Positive Human Serum, containing Preservative. 
Reagent 6 
Color Reagent: Citrate Acetate Buffer, containing Peroxide & 3, 3', 5, 5' 
Tetramethylbenzidine (TMB) solution. 
Reagent 7 
Stopping solution: Mineral Acid 
Reagent 8 
Microwell Strips: Coated with anti-HBs Antibody. 
 
Assay Procedure 
Required number of Microwell strips to perform the test was taken out and the wells 
were labeled appropriately. 
Remaining strips were kept in pouch provided, along with absorbent. 
 100 µL of Sample Diluent (Reagent 1) was added to Test and Control wells of 
the Microwell Strips (Reagent 8) except Blank well i.e. 1A. (as in Fig.). The 
Blank well was left empty. 
 100 µl of Negative Control (Reagent 4) was added to 1B, 1C & 1D and 100 
µL of Positive Control (Reagent 5) to 1E and 1F. To rest of the wells, 100 µL 
of samples were added to the rest of the wells. 
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 Contents were properly mixed and the Microwell was covered with Adhesive 
Strip Covers provided and allowed to stand at Room Temperature for 60 
minutes. 
 The Adhesive Strip Covers were removed and discarded. The content of the 
wells were decanted into a waste container. The wells were filled with 
approximately 350 µL of diluted Washing Buffer (Reagent 3) and allowed 
soak time of 30 seconds per well (the Auto washer was programmed for soak 
time of 30 seconds) and then decanted in the waste container. The procedure 
was repeated for 4 more times. The wells were drained on a disposable 
absorbent pad or towel and tapped firmly to remove excess of fluid. Care was 
taken not to scratch the inner surface of the well with pipette tips or tissue 
paper. 
 50 µl of Conjugate Stabilizer (Reagent 2A) was added first, followed by 100 
µL of Conjugate (Reagent 2) to each well except 1A i.e. Blank well. The 
contents of Microwells were mixed and the strips were covered with fresh 
Adhesive strip covers provided. 
 It was incubated for 30 minutes at Room Temperature and then the Adhesive 
Strip Covers were removed and discarded. 
 Each Microwell was washed five times. 
 Microwells were tapped on a fresh disposable absorbent pad or towel and 
tapped firmly to remove all moisture present in the wells. Care was taken not 
to scratch the inner surface of well with pipette tips or tissue paper. 
 100 µl of Colour Reagent (Reagent 6) was added in all the Microwells 
including the Blank well. It was covered with fresh Adhesive Strip Covers. 
 Incubated at Room Temperature far 30 minutes. 
 Adhesive Strip Covers were removed and discarded and 100 µL of Stopping 
solution was added (Reagent 7) to all the Microwells to stop the reaction. 
 The contents of the Microwells were mixed well by agitating the strips gently 
for 5-10 seconds. 
 The results were read in Bichromatic (450+630 nm) mode. Absorbance 
readings were taken after blanking with A1 well (Reagent Blank). Readings 
were taken within 30 minutes of addition of Stop Solution (Van Weemen et 
al., 1971; Voller et al., 1978 and Fields et al., 1983). 
o Absorbance of Negative Control Should be <0.2 
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o Absorbance of Positive Control Should be >1.00 
o Absorbance of Reagent Blank should be <0.100, when read in 
Bichromatic mode. 
Cut Off Calculation 
The Cut-off value was calculated based on the mean absorbance of 3 Negative 
Controls and addition of a factor (0.10) i.e. 
Cut off = NCX + 0.10 
Interpretation of Results 
1. All samples with absorbance less than Cut off value were considered Non-
Reactive for HBsAg. 
2. Samples with absorbance more than Cut off value were considered Reactive 
and rested to confirm the positivity. 
 
Screening for the detection of Hepatitis B by PCR 
Hepatitis B Virus DNA detector Test was done at Ranbaxy Laboratories, Mumbai. 
Detection of HBV by PCR would be desirable for a number of reasons… 
a) Direct viral detection should contribute significantly in clarifying the status of 
individuals with intermediate serologies. 
b) Variant strains of HBV cannot produce HbeAg in serum when an active 
infection is present. Therefore HbeAg to monitor disease progression may be 
of limited utility (Hoofnagle, 1990). 
c) Also individuals under treatment have undetectable amounts of HbeAg but 
actively replicating HBV. 
Method 
For the quantitative assay, viral DNA was isolated from serum (Ansubel et al., 1990). 
For PCR amplification primers complimentary to the pol gene of the virus was used 
as it is highly conserved (Baginski et al., 1990). Detection of amplified sequence was 
done by 2% agarose gel electrophoresis (Sambrook, 1989).  
Interpretation: 
Each sample was run with a positive and a negative control visualizing a band of 244 
bp in the test sample and positive control compared against a low mass DNA ladder 
confirmed HBV positivity. The negative control should not have any bands. Because 
of the exquisite sensitivity of PCR, special care are being taken to avoid cross 
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contamination of samples beginning from the collection till end of testing to avoid 
any false positive results. 
 
Screening for HCV 
Test was done by third generation Enzyme Immunoassay Kit for the detection of 
antibody to Hepatitis C Virus (Anti- HCV) in human serum or plasma by HCV 
MICROLISA. 
Introduction 
Hepatitis C is a disease caused by viral infection, which is primarily a result of blood 
transfusions or improper needle punctures (Dienstag, 1983). Since Hepatitis C is a 
significant problem for public health management, screening for Hepatitis C, 
therefore is urgently needed (Alter 1988; Tabor et al., 1980).  
Principle of the Test 
The kit adopts the second antibody “sandwich principle” as the basis for the assay to 
detect antibodies to Hepatitis C Virus. 
The SP-NANBASE C-96 3.0 is an enzyme immunoassay kit, which employs 
synthetic HCV peptides and recombinant HCV antigens for the detection of 
antibodies to HCV in human serum or plasma. These antigens, which are reactive 
with the predominant antibodies of HCV, constitute the solid phase antigenic 
absorbent. When human serum or plasma added to the well, the HCV antigens and 
Anti-HCV will form complexes on the wells if Anti-HCV is present in the specimen. 
The wells are washed to remove the unbound materials. The Conc. Anti-Human IgG-
HRPO Conjugate is added to the well results in the formation of (HCV)·(Anti-
HCV)·(Anti-human-IgG-HRPO) complex. After washing out the unbound conjugate, 
TMB substrate solution is added for the color development. The intensity of color 
development is proportional to the amount of antibodies present in the specimen. 
Contents of the kit 
1. HCV Antigens Plate: Microtiter plate coated with HCV antigens. 
2. Concentrated Anti-Human-IgG·HRPO Conjugate: Contained anti human IgG, 
Peroxidase in buffer with Bovine serum. Preservatives: 0.01% Thimerosal and 
0.003% Gentamycin. 
3. Anti-HCV Positive Control: Inactivated human plasma positive for antibody 
to HCV. Preservative: 0.1% Sodium azide. 
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4. HC Negative Control: Normal Human Plasma non-reactive for antibodies to 
HCV. Preservative: 0.1% Sodium azide. 
5. Specimen diluents C: Tris-buffer with bovine serum and Tween-20. 
Preservative: 0.1% Sodium azide. 
6. Conjugate diluents: Tris-buffer with bovine serum and Tween-20. 
Preservatives: 0.01% Thimerosal and 0.03%Gentamycin. 
7. TMB Substrate solution A: 0.6 mg/ml of 3, 3’, 5, 5’- Tetramethyl-benzidine 
solution. 
8. TMB Substrate solution B: Citric acid buffer with H2O2. 
9.  Washing Solution D Concentrate: Phosphate buffer with Tween-20. 
10. 2 N Sulfuric Acid. 
Test Procedure 
1. All reagents and specimens were brought to room temperature (20-30°C) 
before beginning the assay. The reagents were gently mixed well before use. 
2.  Two wells were kept reserved for blanks. No specimen or specimen diluents 
were added in that. 
3.  Needed number of wells for Blanks was prepared, two wells for Negative 
control, three wells for Positive control, and one well for each specimen. 
4. Sampling: 1:21 dilution of each control and specimen with specimen diluents 
were made. 
5. 10 µl of each control or specimen into the well of pre-dilution plate was 
dispensed. 
6. 200 µl of specimen diluents was added to each well and mixed well. 
7. 100 µl of each diluted control or specimen was transferred to the 
corresponding wells in HCV Antigens Plate. 
8. The plate was sealed with an adhesive slip & incubated in a 37 °C water bath 
or circuited incubator for 60 minutes. 
9. At the end of the incubation period, the adhesive slip was removed and 
discarded and the plates were washed by following the plate washing 
procedure. 
10. 100µl of the diluted Conjugate was added in each well except two blanks. The 
plate was sealed with an adhesive slip, and incubated as in step 8 for 30 
minutes. 
11. Step 9 was repeated. 
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12. Equal volume of TMB Substrate Solution A and Substrate Solution B were 
mixed in a clean container immediately prior to use.  100 µl of mixture was 
added to each well including two blank wells. 
13. The plate was covered with Black Cover and incubated at RT for 30 minutes. 
14. The reaction was stopped by adding 100 µl of 2 N Sulfuric Acid to each well 
including two blanks. 
15. Absorbance of Controls and Test Specimens were determined within 30 
minutes at 450 nm with a dual filter instrument.  
Calculation and Determination 
1. Calculation of NCx  
Example: 
  NC             Absorbance 
1 0.045 
2 0.060 
                   NCx = (0.045 + 0.060) ÷ 2 = 0.053  
2. Calculation of PCx  
                  Example: 
                    PC              Absorbance 
1 1.510 
2 1.826 
3 1.305 
                   PCx = (1.510 + 1.826 + 1.305) ÷ 3 = 1.547 
3. Calculation of P-N Value  
P-N = PCx – NCx 
Example: 1.547-0.053 = 1.494 
                 P-N value must be ≥ otherwise the test is invalid. 
4. Determination of Cutoff Value and Cutoff Index 
Cutoff value = NCx + 0.25 X PCx 
Example: 
Cut off Value = 0.053 + 0.25 X 1.547 
                      = 0.053 + 0.387 
                      = 0.440 
Cutoff Index = Sample OD Value/ Cutoff Value 
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Example: 
Sample Value is 0.596 
Cutoff index = 0.596/0.440 = 1.355 
Interpretation of result 
 Specimens with absorbance values LESS than the CUTOFF VALUE were 
considered NON-REACTIVE by the criteria of GBC’s SP-NANBASE C-96 
3.0 
 Specimens with absorbance values GREATER than or EQUAL to the 
CUTOFF VALUE were considered initially REACTIVE. They were retested 
in duplicate. If both CUTOFF INDEXES of the duplicate were GREATER 
than 1.5, the specimen was considered to be repeatedly REACTIVE for 
antibodies to HCV by the criteria of GBC’s SP-NANBASE C-96 3.0  
 Initially reactive specimens, of which both CUTOFF INDEXES of the 
duplicate retest are LESS than 1.0, was considered NON-REACTIVE for 
antibodies to HCV. 
 
Screening of CMV IgM 
Introduction 
Cytomegalovirus (CMV) infections are widespread and approximately half of the 
adult population has antibodies to CMV. CMV infections are frequent in individuals 
with deficient cellular immunity such as cancer patients or person with AIDS, or those 
receiving immunosuppressive agents. About 2% of pregnant women have either a 
primary or a reactivated CMV infection during pregnancy and it is estimated that 10-
20% of congenitally infected newborns will show evidence of disease (Marx 1985, 
Kalmin 1981) (Stern and Tucker 1973). The detection of antibodies against CMV 
may be value as an aid in the diagnosis and in determining the immune status of the 
patient (Ahlfors, 1981). The test is done by Equipar diagnostic kit. 
Principle 
CMV antigens are fixed to the interior surface of microwells. Patient’s serum is added 
and antibody present to cytomegalovirus will bind to these antigens. The microwells 
are washed to remove unbound serum proteins. Antibodies conjugated with 
Horseradish Peroxidase enzyme and directed against human IgG are added and will in 
turn bind to any human IgG present. The microwells are washed to remove any 
unbound conjugate and then chromogen/substrate is added. In the presence of 
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peroxidase enzyme the colorless substrate is hydrolyzed to a colored end-product. The 
color intensity is proportional to the amount of antibodies present in the patient’s 
serum. 
Components: 
1. Microwell Plate 
2. Negative control 
3. Low positive control 
4. High positive control 
5. Sample diluents 
6. Wash solution 
7. Enzyme conjugate 
8. TMB- Substrate 
9. Stop solution 
 
Assay procedure 
 Required numbers of microwells were placed in the microwell holder. One 
end of each strip was marked for orientation. 
 The samples were diluted 1:100 with serum diluents. As calibrators were 
ready for use they were not diluted. 
 100 µl of negative control, low positive control and high positive controls 
were pipetted into subsequent wells. 
 The microwells were incubated at room temperature for 15 minutes. 
 Microwells were washed by inverting and flicking them into a sink. Wash was 
repeated 3 times with wash buffer. 
 100 µl of Enzyme conjugate was pipetted into each well. 
 The microwells were incubated at room temperature for 15 minutes. 
 Microwells were washed. 
 100 µl of TMB-Substrate was pipetted into each well. 
 The microwells were incubated at room temperature for 5 minutes. 
 100 µl of Stop solution was pipetted into each well using the same pipetting 
sequence. 
 Color intensity of the solution in each well was measured by using a 
microwell reader with a 450 nm filter. 
 Standard curve was prepared and results were calculated. 
56 
 
Quality control 
Each time the assay is run the Low Positive and the High Positive Standard should be 
run in duplicate. The mean OD values for the standards should fall within the 
following ranges: 
 
Control OD Range 
Negative control <0.250 
Low positive control >0.300 
High positive control >0.700 
 
The results are reported as Activity Index Values. 
Reporting results: The activity index values of the controls and the serum samples 
were read from the standard curve prepared for each run. 
 
Syphilis screening test 
Principle 
The RPR Syphilis screening test is a macroscopic non-treponemal flocculation card 
test for detection and to quantify the regain, an antibody like substrate present in 
serum or plasma and spinal fluid from syphilitic persons. 
Qualitative test procedure 
 All reagents and samples were brought to room temperature. 
 Using the disposable sample dropper, one drop of serum was dispensed onto a 
separate circle on the test card.  Fresh disposable sample dropper for each 
sample was used.  The positive and negative control sera were kept on 
respective circles on test card. 
 Using the disposable stirring rod, spread the sample was spread over the entire 
area of the test circle. 
 The carbon antigen was mixed well and one drop of “free fall” Antigen 
suspension was placed onto each specimen using 20G dispensing needle.  
 The card was placed on a rotator and rotated for 8 minutes at 100 rpm. 
Immediately after 8 minutes rotation, the results were read macroscopically in 
good light. (McGrew et al., 1968; Hunter et al., 1964 and Larsen et al., 1981) 
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Qualitative test results 
Reactive: The presence of large aggregates in the center or the periphery of the test 
circle. 
Weakly Reactive: The presence of small or fine aggregates. 
Non- Reactive: Smooth grey appearance with no aggregates visible. 
 
Culturing of blood 
Bacteraemia 
The presence of the bacteria in the blood is called bacteraemia. It is usually 
pathological although transitory asymptomatic bacteraemia can occur during the 
course of many infections and following surgical procedures.  
 
Septicemia 
This is a clinical term used to describe severe life threatening bacteraemia in which 
multiplying release toxins into the blood stream and trigger the production of 
cytokines causing fever, chills, toxicity, tissue anoxia, reduced blood pressure, and 
collapse. Septic shock is usually complication of septicemia with Gram negative 
bacilli, and less frequently, Gram positive organisms. 
 
Procedure 
 10-12 ml blood was inoculated into Columbia agar diphasic medium (Hi-
Media Make) aseptically. 
 The medium was incubated up to 7 days. 
 Simultaneously, buffy coat smear was prepared from EDTA blood. 
 Smear was stained with Gram’s stain &  Giemsa stain. 
 The smear was examined microscopically and reported accordingly. 
 After an overnight incubation the diphasic culture medium was examined for 
growth and turbidity. 
 Subculture was done on Blood Agar & MacConkey agar from 2nd day 
onwards. 
 Diphasic culture media were re-incubated. 
 Blood agar & MacConkey agar were examined for bacterial growth 
(Cheesebrough, 2000). 
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Examination of blood for malaria parasites 
Malaria is a major public health problem and cause of suffering premature death in 
tropical and subtropical countries. In many endemic areas, it is becoming increasingly 
difficult to control because of the resistance of the parasite to anti-malarial drugs and 
the failure of vector control measures. 
 
Detecting and identifying malaria parasite in blood films 
Blood was collected, followed by capillary blood method for Malaria blood films 
preparation. EDTA venous blood also can be used. 
 
Capillary blood method (Thin and thick blood films on the same slide) 
 Using a completely clean grease- free microscope slide  a small drop of blood  
was added to the centre of the slide and a larger drop about 15 mm to the right. 
 The thin film using a smooth edged slide spreader was spread immediately. 
Blood from anemic patients needed spreading more quickly with spreader held 
at a steeper angle. 
 Without delay, the large drop of blood was spread to make the thick smear. 
The slides were labeled with the date and the patient’s name and number.  
 The blood films were allowed to air dry with the slide in a horizontal position 
and placed in a safe place. 
 Absolute methanol and ethanol were used to fix thin blood films.  
 Staining of malaria parasite was done by Field’s stain - one of Romanowsky 
stain  
Reporting 
When the slide is completely dry after staining procedure, a drop of immersion oil 
was applied to an area of the film which appeared mauve colored. 
Malarial parasites were examined in microscope using the 40X and 100X objectives.  
The presence of parasites (trophozoites, schizonts, gametocytes) was reported and 
also whether malaria pigment is present in white cells.  
 
Screening of Hematological parameters 
All the samples were screened by poCFH-100i Automated Hematology Analyzer by 
Sysmax, Transasia. 
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It shows parameters like WBC, RBC, HGB, HCT, MCV, MCH, MCHC, PLT, 
LYM#, LYM%, MXD#, MXD%, NEUT#, NEUT%, RDW-SD, RDW-CV, PWD*, 
MPV, P-LCR.It shows histogram of WBC, RBC and PLT. 
Detection principles 
WBC  : Electric impedance method. 
RBC/ PLT : Hydrodynamic focusing DC detection method. 
HGB  : Non-Cynaide hemoglobin analysis method. 
Test procedure: Serum samples were run on poCH – 100i which is an auto analyzer 
instrument. 
 
Screening of blood groups (ABO) 
Monoclonal agglutinating sera were used for the determination of human blood 
groups (ABO) by Span Diagnostic kit. 
Introduction 
Discovery of ABO blood grouping in 1900 by Karl Landsteiner was a milestone in the 
history of Immunohematology. He reported the presence of two antigens viz. A and 
B, on the surface of human red blood cells (RBCs). Based on this discovery, he 
divided RBCs into three groups viz. A, B and O. Very soon, in 1902, a fourth group 
viz. AB was discovered by Decastello and Sturli. ABO blood group system is the 
most significant blood group system used for the transfusion and organ 
transplantation purposes. According to this system, the blood of each individual 
carries an antibody directed against the antigen which is absent from the person’s 
RBCs. 
 
Principle 
Test is based on hemagglutination reaction. Human RBCs possessing A and/or B 
antigen will agglutinate with the corresponding antibody. Agglutination of RBCs with 
SPANCLONE ANTI-A Monoclonal, SPANCLONE ANTI-B Monoclonal and/or 
SPANCLONE ANTI –A B Monoclonal is a positive result and indicates the presence 
of the corresponding antigen. Absence of agglutination of RBCs with SPANCLONE 
ANTI-A Monoclonal, SPANCLONE ANTI-B Monoclonal and/or SPANCLONE 
ANTI-AB Monoclonal is a negative test result and indicates the absence of the 
corresponding antigen. SPANCLONE ANTI-AB is especially useful in detecting the 
60 
 
weak variants of A and B which are occasionally missed by the routinely used 
Monoclonal ANTI-A and ANTI-B sera. (Dacie and Lewis, 2001) 
 
Reagents 
SPANCLONE ANTI-A Monoclonal 
SPANCLONE ANTI-B Monoclonal 
SPANCLONE ANTI-AB Monoclonal 
 
Assay Procedure 
 10% suspension of RBCs in normal saline was prepared. Alternatively, 
oxalated whole blood was used. 
 Three circles were marked on a glass slide and labeled them as A, B and AB. 
 One drop of the appropriate blood grouping reagent was placed at the above 
marked area. 
 One drop of 10% cell suspension or oxalated whole blood was placed to each 
of the marked area. 
 With the separate applicator sticks the contents were mixed well and spread 
over an area of approximately 2cm in diameter. The slide was tilted back and 
forth for 2 minutes. 
 The evidence of agglutination was observed macroscopically (Mollison, 
1997). 
Interpretation of result 
Positive: Agglutination indicates positive reaction. 
Negative: No agglutination indicates negative reaction. 
Possible reactions with SPANCLONE ANTI-A Monoclonal, SPANCLONE ANTI-B 
Monoclonal and SPANCLONE ANTI-AB Monoclonal and their interpretations are 
shown in the following table. 
Screening of ANTI-D (Rho)  
The test was done by using kits of Span diagnostics 
Introduction 
About 95% of the Indian population and 85% of the Caucasian origin possess D (Rho) 
antigen on their erythrocytes. Human red blood cells are classified as “Rh-Positive” or 
“Rh-Negative” depending upon the presence or absence of this antigen on their 
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surface. SPANCLONE ANTI-D (Rho) Monoclonal is used for the detection of the 
presence of Rho antigen on the red blood cells. 
Principle 
Human red blood cells possessing D antigen are agglutinated by the antibody, 
directed against D (Rho) antigen. 
Assay Procedure 
 Whole blood or 40% suspension of red blood cells in saline was used as 
specimen. 
 One drop each of SPANCLONE Anti-D (Rho) Monoclonal and whole blood 
40% suspension was placed on a clean glass slide. 
 The contents were mixed well with an applicator stick, and spread over an area 
of approximately 2 cm in diameter. The slide was tilted back and forth for 2 
minutes. 
 The evidence of agglutination was observed macroscopically (Thomson et al., 
1986; Goossens et al., 1987). 
Interpretation of result 
 Presence of agglutination indicates D (Rho) Positive, cell type.  
Absence of agglutination generally indicates D (Rho) Negative, cell type. 
 
Screening for S.G.P.T. detection specially in Thalassemic patients 
All the samples were screened by S.G.P.T. IFCC method, Kinetic by ERBA S.G.P.T. 
Test kit. 
 
Principle 
L-Alanine + 2-Oxoglutarate 
ALT 
  Pyruvate + L- Glutamate  
Pyruvate + NADH  
LDH
   L- Lactate + NAD  
ALT: Alanine aminotransferase 
LDH: Lactate dehydrogenase 
 
Sample 
Unhemolysed serum or heparinised plasma, Anticoagulants such as heparin or EDTA 
are suitable. ALT is stable for 3 days at 2-8ºC. 
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Assay procedure 
 100 µl test serum was added to 1000 µl of working reagent and aspirated to 
chemical analyzer. 
 The reading was noted (Bradly et al., 1972; Wolf et al., 1972; Wroblewski et 
al., 1956). 
 
Quality Control 
To ensure adequate quality control each run should include assayed Normal and 
Abnormal controls. 
 
Normal Values 
Females: Up to 22 IU/L at 30°C or 0-31 IU/L at 37°C 
Males:    Up to 29 IU/L at 30°C or 0-40 IU/L at 37°C 
 
Screening of Iron & TIBC Level by Crest Biosystems 
Test is based on Ferrozine Method for the determination of Iron and Total Iron 
Binding Capacity in serum. 
 
Summary 
Iron found in blood mainly present in the hemoglobin of the RBCs. Its role in the 
body is mainly in the transport of oxygen and cellular oxidation. Iron is absorbed in 
the small intestine, and bound to a globulin in the plasma, called transferrin, and 
transported to the bone marrow for the formation of hemoglobin. Increased serum 
iron levels are found in hemolytic anemias, hepatitis, lead and iron poisoning. 
Decreased serum levels are found in anemias caused by iron deficiency due to 
insufficient intake or absorption of iron, chronic blood loss, late pregnancy and 
cancer. Increase in TIBC is found in Iron deficient anemias and pregnancy. Decrease 
in TIBC is found in hypoproteinemia, hemolytic/ pernicious/ sickle cell anemias, 
inflammatory diseases and cirrhosis. 
Principle 
Iron, bound to Transferrin, is released in an acidic medium and the Ferric ions are 
reduced to Ferrous ions. The Fe (II) ions react with Ferrozine to form a violet colored 
complex. Intensity of the complex formed is directly proportional to the amount of 
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iron present in the sample. For TIBC, the serum is treated with excess Fe (II) to 
saturate the iron binding sites on transferring. The excess Fe (II) is absorbed and 
precipitated and the Iron content in the supernatant is measured to give the TIBC. 
 
Fe (III) in acidic medium →Fe (II) 
Fe (II) + Ferrozine →Violet Colored Complex 
 
Normal Reference Values 
Serum Iron (Males)                 : 60 – 160 µg/dl 
                   (Females)              : 35- 145 µg/dl 
                   (Neonates)            : 150-220 µg/dl 
 
 
TIBC                                      : 250- 400 µg/dl 
UBIC                                       : 160- 360 µg/dl 
 
Procedure 
Wavelength/ Filter         : 570 nm (Hg 578 nm) / Yellow 
Temperature                   :  Room temperature 
Light Path                      :  1 cm 
 
Iron Assay 
The reagents and serum samples were pipette into clean dry test tubes labeled as 
Blank (B), Standard (S), Sample Blank (SB) and Test (T): 
Addition Sequence B (ml) S (ml) SB (ml) T 
(ml) 
Iron Buffer Reagent (L1) 1.0 1.0 1.05 1.0 
Distilled water 0.2 -   - - 
Iron Standard (S) - 0.2  - - 
Sample - - 0.2 0.2 
Iron Color Reagent (L2) 0.05 0.05   - 0.05 
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The reagents were mixed well and incubated at R.T. for 5 min. The absorbance was 
measured of the blank (Abs. B), Standard (Abs. S), Sample blank (Abs. SB) and Test 
Sample (Abs. T) against D.W. 
 
TIBC assay 
The reagents and samples were pipette into a clean dry test tube 
 
Serum 0.5 ml 
TIBC Saturating Reagent (L1) 1.0 ml 
 
The contents were mixed well and allowed to stand at RT for 10 min and added to 
that reagent 2 (L2) 
TIBC Precipitating Reagent (L2) Approx. 50 mg 
  
The contents were mixed well and allowed to stand at RT for 10 min and centrifuged 
at 2500–3000 rpm for 10 min to obtain a clear supernatant. The iron content was 
determined in the supernatant as above mentioned iron assay (Siedel et al., 1984). 
 
Calculations 
Iron (µg/dl) = Abs.T – (Abs. SB + Abs. B)/ Abs.S – Abs.B ×100 
TIBC (µg/dl) = Abs.T – (Abs. SB + Abs. B)/ Abs.S – Abs.B ×300 
UIBC (µg/dl) = TIBC µg/dl - Iron in µg/dl  
 
Prothrombin Time (PT) 
Principle 
This test reflects the overall efficiency of the extrinsic system. It is sensitive to 
changes in factor V, VII and X, and less so to factor II (prothrombin). It is also 
unsuitable for detecting minor changes in fibrinogen level, but may be abnormal if the 
fibrinogen level is very low or if there is an inhibitor present. The sensitivity of the 
test is influenced by the reagent and technique used and it is important to establish a 
reference range locally (Biggs and McFerlane 1962; Hirsh et al., 1995). 
65 
 
The pathway measured by the prothrombin time is shown in Figure 11.1 (Colman and 
Hrish 1994). The PT reagent, often termed thromboplastin, contains tissue factor and 
phospholipids. 
 
Equipment 
• Test tubes 
• Stopwatch 
• Pipettes 
• Waterbath 
• Coagulometer 
 
Reagents 
Many suitable reagents are commercially available. Notes on reagent selection are 
included in Section 8. 
• Thromboplastin (this may contain calcium chloride) 
• 25 mM Calcium chloride (only required, if thromboplastin reagent does not contain 
calcium.) 
 
Manual Method   
 To the first two tubes: 
 ml normal plasma was placed and warmed to 37°C for 2 minutes. 
 ml pre-warmed (to 37°C) thromboplastin reagent (if calcium is present in the 
reagent), were added, stopwatch started, gently mixed by shaking the tube and 
clotting times were recorded. 
 Repeated for each test sample. 
 Patient's clotting time were reported in seconds. 
Results/ Interpretation 
Duplicate clotting times should not differ by more than 10%. 
 
Notes: 
If thromboplastin reagent does not contain calcium the test procedure is 0.1 ml 
plasma, 0.1 ml thromboplastin and clot with 0.1 ml pre-warmed 25mM calcium 
chloride. 
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Activation of factor IX by tissue factor – factor VII occurs in vivo. Under the 
conditions of most PT tests factor X is so strongly activated that the assay is 
insensitive to deficiency of factor IX or VIII. 
 
Thromboplastin/calcium chloride should be pre-warmed for 5-30 minutes prior to use. 
Clotting times are normally influenced by the use of different coagulometers 
depending on how and when the end point is detected. This underlines the importance 
of establishing normal ranges for the method currently in use in the laboratory. 
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Activated Partial Thromboplastin Time (APTT) 
Principle 
This is a non-specific test of the intrinsic system. Taken together with a normal 
prothrombin time, it is the most useful screening test for detecting deficiencies of 
factors VIII, IX, XI and XII (Biggs 1972). 
The APTT will also be prolonged in any deficiency involving the common pathways 
(Deficiencies of factors V, X, II and to a lesser extent fibrinogen) and in the presence 
of inhibitors. The presence of some therapeutic inhibitors of coagulation, such as 
heparin, will also prolong APTT. It is important to rule out these treatments as a cause 
of prolonged APTTs before continuing with other tests (Hoffmann and Neulendijk 
1978). 
The pathway measured by the APTT is shown in Figure 12.1. 
 
Equipment 
• Pipettes 
• Stopwatches 
• Water bath 
• Test tubes 
 
Reagents 
• APTT reagent (There are many suitable commercial reagents which may differ in 
sensitivity.) 
• 25mM Calcium Chloride   
 
Method 
 Tubes containing calcium chloride were placed at 37oC for 5 minutes prior to 
use. 
 0.1 ml of APTT reagent was pipette into each of 2 glass clotting tubes at 
37oC. 
 0.1 ml control plasma was pipette into first tube. Master stopwatch started. 
Mixed. 
 0.1 ml control plasma was added to second tube. Mixed. 
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 After 5 minutes 0.1 ml calcium chloride was added to each tube in succession 
and started new stopwatch for each tube. Mixed.  
 Time for clot formation was recorded. 
 All tests were performed in duplicate (CRC, 1980). 
 
Results/ Interpretation 
A normal range should be established locally. 
A long APTT with a normal PT indicates a possible deficiency of factor VIII, IX, XI, 
XII, high molecular weight kininogen, prekallikrein or the presence of an inhibitor. In 
cases with a long APTT, an equal mixture of normal and test plasma should be tested 
(i.e., a mixture of 1 part test and 1 part normal plasma, called a 50:50 mix, below). If 
the APTT corrects by more than 50% of the difference between the clotting times of 
the normal and test plasma, a factor deficiency is indicated. Poor correction suggests 
an inhibitor, possibly to one of the clotting factors in the system or of the non-specific 
type, such as lupus anticoagulant. 
 
Note: 
As for PT, clotting times can be influenced by the use of coagulometer. Within test 
plasmas, high levels of one clotting factor can compensate for lower levels of other 
factors. For example, a very high level of factor VIII during acute phase reaction can 
lead to a normal APTT in the presence of reductions of factor IX or XI which could 
be clinically important. If a patient has the appropriate personal or family history 
suggestive of a bleeding disorder, fuller investigation, including specific factor assays, 
may be justified even though the APTT is normal. 
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Pathway Measured by APTT 
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Mixing Tests for further Investigation of Abnormal PT and APTT 
Principle 
Plasma samples found to have abnormal screening tests, i.e. PT/APTT, can be further 
investigated to determine the cause of the abnormality. Information on the nature of 
the defect can usually be obtained by mixing experiments. The test plasma is mixed 
with normal plasma or plasma with a known coagulation defect. The test is repeated 
noting the degree of correction. 
 
First of all it is important to demonstrate that the defect in a patient’s plasma is 
corrected with normal plasma in order to eliminate the presence of an inhibitor. 
Correction of the abnormality by the addition of one of the reagents described below 
indicates that the added reagent must contain the substance deficient from the test 
sample. 
 
Abnormal screening tests are repeated on equal volume mixtures (termed 50:50, 
below) of additive and test plasma (CRC 1980). 
 
The agents which can be used for mixing tests are as follows: 
• Normal plasma 
• Aged plasma 
• Adsorbed plasma 
• Factor VIII deficient plasma 
• Factor IX deficient plasma 
 
The tables below show how the results from mixed tests should be interpreted. 
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Factor Assays based on APTT 
(One stage Assay of FVIII: C, FIX, FXI or FXII) 
Principle 
The one-stage assay for factor VIII will be described here. The assay compares the 
ability of dilutions of standard and test plasmas to correct the APTT of a plasma 
known to be totally deficient in factor VIII but which contains all other factors 
required for normal clotting. For factors IX, XI and XII the assay is essentially the 
same and is performed by substituting the relevant deficient plasma for factor VIII 
deficient, and after selection of the appropriate reference plasma. 
 
Equipment 
• Plastic tubes 
• Pipette 
• 75 x 10-mm glass tube 
• Ice bath 
• Water bath 
 
Reagents 
Platelet poor citrated test and standard plasma: 
The standard plasma used should be either a locally prepared plasma pool, 
kept at -70°C or lower or commercial standard plasma. In either case, this 
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reference plasma must be calibrated against an international standard for factor 
VIII. It is not acceptable to assume that a pooled normal plasma has 100 u/dl 
factor VIII:C since this is often not the case. 
Factor VIII deficient plasma 
This is available commercially or may be collected from a donor whose factor 
VIII level is less than 1 u/dl, who has no anti-VIII antibodies, has received no 
treatment for 2 weeks and has normal liver function tests. Abnormal liver 
function can lead to a decrease in other clotting factors. Such a decrease can 
lead to a non-specific assay. This plasma can be stored in aliquots at -35ºC. It 
is preferable to use factor VIII deficient plasma produced by immunodepletion 
of factor VIII from normal plasma using a monoclonal antibody. This type of 
material is available commercially. The commercial preparation has the 
advantage of viral safety compared to plasma from people with haemophilia 
who have been treated with plasma products. However, not all 
immunodepleted plasma is found to be < 1 u/dl and care should be taken to 
check this. 
APTT reagent 
Owren's buffered saline (OBS) or glyoxaline buffer 
25mM CaCl2 
 
Method 
 1: 10 dilutions of standard and test plasma in buffered saline in plastic tubes 
were made.  
 Using 0.2 ml volumes, doubling dilutions in OBS of standard and test plasma 
from 1/10 to 1/40 in plastic tubes were made. All dilutions were kept on ice as 
factor VIII is labile (easily destroyed). (This is only necessary if dilutions are 
not tested immediately after preparation or if room temperature exceeds 
25°C). 
 0.1 ml of each standard dilution was pipetted into a 75 x 10-mm glass tube. 
 0.1 ml of factor VIII deficient plasma was added and transferred to 37oC 
water bath. 
 0.1 ml of APTT reagent was added and incubated for 5 minutes. 
 At 5 minutes 0.1 ml CaCl2 was added and the clotting time was recorded. 
 A "blank" should also be set up as follows: 
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0.1ml OBS 
0.1ml FVIII deficient plasma 
0.1ml APTT reagent 
 Incubated for 5 min. 
 0.1ml CaCl2 was added. 
 The clotting time of the blank should be longer than the time of 1% FVIII 
activity of standard from the calibration graph. If the time is shorter this 
indicates that the plasma is not totally deficient in factor VIII and thus is not 
suitable for the test (Biggs, 1972). 
 
Results/ Interpretation 
The results were plotted on log/log or log/linear graph paper. 
The 1: 10 dilution is arbitrarily assigned a value of 100%, the 1: 20 a value of 50%, 
and the 1: 40 a value of 25%. Straight lines, parallel to each other, should be obtained. 
 
Read off concentration of test sample as shown on graph. In this example the test has 
a FVIII concentration which is 7% of that in the standard. If the standard has a 
concentration of 85 µ/dl, the test has a concentration of 85 µ/dl x 7% = 6 µ/dl.  
If the lines are not parallel, the assay should be repeated. 
Non-parallel lines may occur due to technical error. If technical error has been 
eliminated, nonparallel lines may be due to the presence of an inhibitor, which would 
show a converging pattern. 
 
Note 
If the test plasma factor VIII concentration is close to zero (i.e., the clotting times of 
all dilutions are similar to the blank) then non-parallel lines may occur. 
Normal Range 
The normal range should be established locally but often has a lower limit of 50-60 
µ/dl. 
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CHAPTER 4 
RESULTS 
 
Risk of infectious complications due to blood transfusion is a major concern. Number 
and types of microbial infections depend on variety of factors as discussed. In 
developing countries like India where medical facilities are sporadic and not up to the 
best of the standards such incidences are obviously high. The risk is increased 
manifold if a person receives multiple blood transfusions.  
 
Present study was conducted to observe incidence of microbial infection in patients 
who receive multiple blood transfusion in and around Rajkot city. Results obtained 
are divided in to five major categories: 
(1) Incidence of Microbial infection and co-relative data in healthy donors 
(2) Incidence of Microbial infection and co-relative data in Thalassaemic patients 
(3) Incidence of Microbial infection and co-relative data in Hemodialysis patients 
(4) Incidence of Microbial infection and co-relative data in Hemophilia patients 
(5) Incidence of Microbial infection and co-relative data in surgical multi 
transfused and leukemia patients 
 
Incidence of Microbial infection and co-relative data in healthy 
donors 
Transfusion transmitted microbial infections such as HIV or Hepatitis or other 
infections are spread in community by apparently “healthy” blood donors. There are 
stringent measures to assure that the donor is adequately healthy while donating 
blood. Age of the donor should be between 18 and 55 years, weight should be above 
45 kg. hemoglobin level should be in the normal range. Above all the donor should 
not be suffering from any major illness such as diabetes, hypertension, or even fever 
of unknown origin. However, infections are still transmitted through blood because of 
various reasons. Seropositivity of some of the markers which are indicative of quality 
of blood is shown in following result.   
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Prevalence of Microbial Infection among Donors 
Figure 1 
 
Year Donor no. HIV (%) HBsAg (%) HCV (%) V.D.R.L.(%) 
2002 5512 51 (0.92) 91 (1.65) 12 (0.21) 37 (0.67) 
2003 5586 31 (0.55) 96 (1.71) 49 (0.87) 62 (1.10) 
2004 5227 32 (0.61) 98 (1.87) 116 (2.21) 60 (1.14) 
2005 6410 40 (0.62) 96 (1.49) 55 (0.85) 71 (1.09) 
2006 6696 27 (0.40) 122 (1.82) 41 (0.61) 94 (1.40) 
2007 7458 72 (0.96) 148 (1.98) 82 (1.09) 95 (1.27) 
 
 
Figure 1 shows microbial infections among donors. In the year 2002, the rate of 
infections of HIV, HBsAg, HCV and V.D.R.L. were 51, 91, 12 and 37 respectively. 
In year 2003, the rate was 31, 96, 49 and 62 respectively. In year 2004, the rate was 
32, 98,116 and 60 respectively. In 2005, the rate was 40, 96, 55 and 71 respectively. 
In 2006, the rate was 27, 122, 41 and 94 respectively. At the end of the study i.e. in 
the year of 2007, the rate was 72, 148, 82 and 95 respectively. 
 
Percentage of donors found to be infected with HIV, Hepatitis B and C virus or 
Treponema pallidum is found varying over the years but there is a clear increase in all 
the four markers from 2002 to 2007. Most remarkable being rise in HCV 
seropositivity-0.21% in the year 2002 to 1.09% in 2007. 
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Statistical analysis of the data 
Anova: Two factor analyses without replication were carried out to find out statistical 
significance of rate of infection over the years. 
SUMMARY Count Sum Average Variance 
2002 4 191 47.75 1091.583 
2003 4 238 59.5 753.6667 
2004 4 306 76.5 1425 
2005 4 262 65.5 573.6667 
2006 4 284 71 1988.667 
2007 4 397 99.25 1144.917 
     
HIV 6 253 42.16667 286.1667 
HBsAg 6 651 108.5 494.3 
HCV 6 355 59.16667 1285.367 
VDRL 6 419 69.83333 490.9667 
 
ANOVA 
Source of 
Variation 
SS df MS F P- value F crit 
Year 6097.333 5 1219.467 2.735593 2.35593 2.901295 
Infection 14245.83 3 4748.611 10.65242 0.000527 3.287382 
Error 6686.667 15 445.7778    
       
Total 27029.83 23     
 
1) Fcal= 2.735593                                                                 Ftab= 2.901295 
Therefore Fcal < Ftab 
Therefore there is no difference in donors blood samples year wise. 
 
2) Fcal= 10.65242                                                                 Ftab= 3.287382 
Therefore Fcal > Ftab 
 
Therefore, there is difference in the rate of infection in donor’s blood samples. 
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In the beginning of our study replacement blood donation was much prevalent 
compare to voluntary blood donation. Change in the pattern of blood donation over a 
period of time was studied.  
Number of Voluntary Vs Replacement Donors 
Figure 2 
 
 
 
 
 
 
 
 
 
.  
 
 
 
 
 
 
 
Year  Voluntary  %  Replacement  %  Total  
2002  1627  29.51  3885  70.48  5512  
2003  1839  32.92  3747  67.07  5386  
2004  2144  41.01  3083  58.08  5227  
2005  2816  43.93  3594  56.06  6410  
2006  3492  52.15  3204  47.84  6696  
2007  3773  50.58  3685  49.41  7458  
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Voluntary donation has increased from about 30% to more than 50% since 2002 to 
2007. 
This result shows increase in seropositivity of the three viral markers in donor 
population so that they can be compared with that of different cohort of 
multitransfused patients. 
 
Donor’s Status 
Figure 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
Year Total HIV +Ve % HBsAg +Ve % HCV +Ve % 
2003 ( at the 
beginning of 
Study 
5586 31 0.55% 96 1.71% 49 0.87% 
2007 ( at the 
end of 
Study) 
7458 72 0.96% 148 1.98% 82 1.09% 
 
 
Figure 3 shows donor’s status in 2003 beginning of the study out of 5586 donors 31 
were HIV, 96 were HBsAg and 49 were HCV Positive, while at the end of the study 
the rate was out of 7458 donors 72 were HIV, 148 were HBsAg and 82 were HCV 
Positive. 
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This figure shows a gradual shift from replacement (commercial?) blood donation to 
voluntary donation. In the year 2002 only 29.51% blood was obtained through 
voluntary donation which exceeded marginally (50.58% Vs 49.41%) in the year 
2007.s 
 
Voluntary/Replacement Donors Ratio 
Figure 4 
 
 
 
 
 
 
 
 
 
 
 
 
No. Year Voluntary % Replacement % Ratio V/R % 
1 2002 29.51 % 70.48% 0.41% 
2 2003 32.92% 67.07% 0.49% 
3 2004 41.01% 58.08% 0.69% 
4 2005 43.93% 56.06% 0.78% 
5 2006 52.15% 47.84% 1.08% 
6 2007 50.58% 49.41% 1.02% 
 
The above result shows a healthy trend of continuous increasing participation of 
voluntary blood donors from 2002 to 2007 but still almost 50% of the requirement of 
blood comes from replacement donors as shown by the ratio for the year 2007 (1.02). 
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Incidence of Microbial infection and co-relative data in Thalassaemic 
patients 
Thalassemia is not a sex chromosome linked genetic disorder. However our study 
showed almost double the number of male patients compare to female patients as 
shown in the Graph. 
                                                     
                           Gender wise distribution of Thalassemia  
                                                         Figure 5 
 
 
Males  81  66.94%  
Females  40  33.06%  
 
Figure 5 shows Thalassemia major rules mainly Males than Females. At K.T. 
Children Hospital in our study we have registered 81 males and 40 female thalassemic 
patients. 
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From the literature review it was evident that Thalassemia  is more prevalent in some 
casts compare to other. In order to check this in our present study castwise 
distribution of Thalassemic patients  
 
Cast wise distribution of Thalassemic patients 
Figure 6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 shows cast wise distribution in Thalassemic patients. Out of 121 patients 
screened, thalassemia mostly observed in Vankar cast that is about 26 (21.32 %), 
Lohana is second most common 16 (13.12%), Muslims 13 (10.66%), Brahmins 11 
(9.02%), Patel 9 (7.38%), Kumbhar 9 (7.38%), Sindhi Lohana 8 (6.56%), Rajput 5 
(4.1%), Bawaji & Aahir shares same numbers i.e. 4 (3.28%), Jain 3 (2.46%) and other 
casts shares approximately 13 (10.66%). 
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Caste Number of Patients % 
Vankar  26 21.32 
Lohana  16 13.12 
Muslim  13 10.66 
Brahmin  11 9.02 
Patel  9 7.38 
Kumbhar  9 7.38 
Sindhi  8 6.56 
Rajput  5 4.1 
Bawaji  4 3.28 
Aahir  4 3.28 
Jain  3 2.46 
Others  13 10.66 
Total  121 100 
 
Thalassemia is most prevalent in scheduled casts followed by Lohana, Muslim, 
Brahmin and other casts in decreasing order as shown in the table.  
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Prevalence of blood group in Thalassemic patients was studied to check the 
preference of any particular blood group. 
 
Blood group wise distribution of Thalassemic patients 
Figure 7 
 
 
 
 
 
 
 
 
 
 
 
 
 
Blood Group Number of patients % 
O 42 34.71 
A 23 19.00 
B 47 38.84 
AB 9 07.45 
 
 
Figure 7  shows in our studies  42 patients out 121 possess Blood group O (34.71%), 
23 out of 121 are of blood group A (19%), 47 out of 121 are of blood group B 
(38.84%) and 9 out of 121 having blood group AB (7.45%). 
Results are similar to the donors data. 
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Rh Factor wise distribution was studied in our thalassemic subjects. 
Prevalence of Rh Factor among Thalassemic Patients. 
Figure 8 
 
 
 
 
 
 
 
 
 
 
 
 
Rh Factor   No.  %  
Rh + ve  113  93.38  
Rh - ve  8  6.62  
 
Above Figure shows Rh positivity in Thalassemic patients. 
113 out of 121 patients are Rh Positive (93.38 %) and only 8 out of 121 patients are 
Rh Negative (6.62%). 
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Generally onset of Thalassemia is detected in a child is about 6 months of age. Only 
hope of survival of such a child is regular blood transfusion at specific time interval. 
Such a vigorous routine of blood transfusion from infancy result in many 
complications ranging from iron overload in vital organs to an array of microbial 
infections. Age-group wise distribution of Thalassemic children reflects this grave 
scenario.                                                 
Age wise distribution of Thalassemic patients 
Figure 9 
 
 
 
 
 
 
 
 
 
 
Age No. % 
0-5 yrs 36 29.52 
6-10 yrs 39 31.98 
11-15 yrs 36 29.52 
16-20 yrs 10 8.2 
above 20 yrs Nil 0 
 
Figure 9 shows age-wise distribution of Thalassemic patients. In our study, there are 
36 patients out of 121 fall in the group of 0-5 years of age (29.52%), 39 patients out of 
121 are of 6-10 years of age (31.98%), 36 patients out of 121 are of 11-15 years of 
age (29.52%), 10 patients out of 121 are of 16-20 years of age (8.2%) and there is no 
patients above 20 years of age in our study. 
Most children undergoing regular blood transfusion in K.T.Children hospital could 
not afford costly iron chelation therapy. As a result life expectancy of these children is 
very pathetic. 
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Blood transfusion requirement of Thalassemic patients depend on many factors such 
as age, spleen status etc.Requirement of blood transfusion per year was studied. 
Requirement of Blood transfusion per year 
Figure 10 
 
 
ml/annum  No.  %  
2000-3000 ml  7  5.74  
3000-4000 ml  13  10.66  
4000-5000 ml  15  12.3  
5000-6000 ml  37  30.34  
6000-7000 ml  22  18.04  
7000-8000 ml  6  4.92  
8000-9000 ml  11  9.02  
9000-10000 ml  4  3.28  
10000-11000 ml  4  3.28  
Above 11000 ml  2  1.64  
 
Figure 10 shows distribution according to blood transfusion per year. 
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Out of 121, 7 patients received 2000-3000 ml of blood/year (5.74%), 13 patients of  
received 3000-4000 ml of blood/year (10.66%), 15 patients received 4000-5000 ml of 
blood/year (12.3%), 37 patients received 5000-6000 ml of blood/year ( 30.34%), 22 
patients received 6000-7000 ml of blood/year (18.04%), 6 patients received 7000-
8000 ml of blood/year (4.92%) and 11 patients out of 121 receives 8000-9000 ml of 
blood/year. 
 
Repeated blood transfusion results in Spleenomegaly in Thalassemic patients. 
Spleen status in Thalassemic patients 
Figure 11 
 
Figure 11 shows that 49% of the patients had spleenomegaly and 37% patients had 
normal size of the spleen. 14% of patients were spleenectomized which make them 
susceptible to microbial infection. However spleenectomy procedure is always 
followed by vaccination to the patients. 
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Vigorous transfusion regime makes thalassemic patients vulnerable to various 
microbial infections. In order to check prevalence of Transfusion Transmitted Viral 
infections following study was carried out. 
                      
                Prevalence of viral infections in Thalassemic patients 
Figure 12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Year Total HIV +Ve % HBsAg +Ve % HCV +Ve % 
2003 ( at the 
beginning of 
Study 
121 02 1.65% 04 3.3% 07 5.78% 
2007 ( at the 
end of Study) 
218 11 5.04% 08 3.66% 18 8.25% 
 
 
Figure 12 shows prevalence of viral infections in thalassemic patients at the beginning 
of the study in 2003 the rate of infection was out of 121 only 2 were HIV Positive, 04 
were HBsAg Positive and 07 were HCV Positive while 2007 the rate was out of 218, 
11 patients were HIV positive, 8 were HBsAg positive and 18 were HCV Positive. 
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Multiple blood transfusions increase the possibility of patients being infected with 
more than one microbial infection. Following study was carried out to check infection 
with more than one virus. 
 
Co-infection with more than one viral infection in Thalassemic Patients. 
Figure 13 
 
 
Total HIV + HBsAg Positive HIV + HCV Positive HBsAg + HCV Positive 
218 2 5 3 
 
Figure 13 indicates higher number of co-infection with HIV+HCV compare to 
HBsAg+HCV and HIV+HBsAg.  
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The estimation of Hemoglobin always reveals the deviation of Hb level from the 
normal. Anything below 13.8 gm% in males and 12.0 gm% in females in considered 
as anemia. 
Estimation of Hemoglobin in Thalassemics 
Figure 14 
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   Hemoglobin % 
1 Thalassemic Average 7.6% 
2 Normal 15% 
 
Above table shows patients with Thalassemia have lower Hemoglobin (Average 
7.6%) than Normal (Average 15.0%). 
Above Figure shows patients with thalassemia shows lower Hemoglobin % in our 
study, Thalassemic patients have average 7.6% of Hemoglobin as compare to normal 
patients have 15.0 % of Hemoglobin. 
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Blood requirement of viral infected thalasemic patients was studied. 
Table 1 
HIV BT ml/year Average ml/year 
Patient 1 12,500 ml/year 9250 ml/year 
Patient 2 6000 ml/year  
 
Table 2 
HBsAg BT ml/year Average ml/year 
Patient 1 6000 ml/yr 6535 ml/yr 
Patient 2 6750 ml/yr  
Patient 3 4000 ml/yr  
Patient 4 6000 ml/yr  
Patient 5 2500 ml/yr  
Patient 6 3750 ml/yr  
Patient 7 16750 ml/yr  
 
Table 3 
HCV BT ml/year Average ml/year 
Patient 1 12000 ml/yr 8150 ml/yr 
Patient 2 11000 ml/yr  
Patient 3 6750 ml/yr  
Patient 4 4000 ml/yr  
Patient 5 7000 ml/yr  
 
It can be seen that though there is individual variation in annual blood requirement of 
patients, average blood requirement is more compare to non infected thalasemic 
patients.  
Table 4 
Serological and Hematological Parameters in Thalassemic patients under the study 
  S.G.P.T. Level 
1 Thalassemic Average 55.1 IU/ml 
2 Normal 6-21 IU/ml 
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Above table shows Thalassemic patients show higher level of S.G.P.T. enzyme 
(55.1IU/ml) than Normal people (6-21 IU/ml). 
 
Table 5 
Comparision of T.I.B.C. levels was carried out. 
  T.I.B.C. Level 
1 Thalassemic Average 506.49 mcg/dl 
2 Normal 228-428 mcg/dl 
 
Above table shows Thalassemic patients show higher level of T.I.B.C. levels (506.49 
mcg/dl) than Normal people (228-428 mcg/dl). 
 
Table 6 
  S.Iron 
1 Thalassemic Average 206.18 µg/100 ml 
2 Normal (Male) 80-175 µg/100 ml 
3 Normal(Female) 60-160 µg/100 ml 
 
Above table shows Thalassemic patients show higher level of S. Iron. (206.18 µg/100 
ml) than Normal people ( Male:80-175 µg/100 ml and Female: 60-160 µg/100 ml) 
 
Table 7 
The hematocrite is about three times the hemoglobin value. It is also referred to as 
Packed Cell Volume (PCV). In anemic condition as in thalassemic expected 
hematocrit value is below normal. Our results are in support with this. 
 
  H.C.T. 
1 Thalassemic Average 21.6% 
2 Normal 37-47% 
 
Above table shows Thalassemic patients have lower levels of H.C.T. (21.6%) than 
Normal people (37-47%). 
94 
 
Table 8 
  R.D.W.-CV 
1 Thalassemic Average 21.44% 
2 Normal 11.5-14.0% 
 
Above table shows Thalassemic patients show higher level of R.D.W.–C.V. (21.44%) 
than Normal people (11.5-14.0%). 
 
Table 9 
Total count of leucocytes is always increased during thalassemia. 
  W.B.C. 
1 Thalassemic Average 12.5 X 10
3 
cells/L 
2 Normal 4.5-11.00 X 10
3 
cells/L 
 
Above table shows Thalassemic patients show high levels of W.B.C. (12.5 X 10
3 
cells/L) than Normal people (4.5-11.00 X 103 cells/L) 
 
Table 10 
RBC count is low. Microcytic anemia is observed. 
  R.B.C. 
1 Thalassemic Average 2.82 X 10
6 
cmm 
2 Normal (Male) 4.5-6.5 X 10
6 
cmm 
3 Normal(Female) 3.9-5.6 X 10
6 
cmm 
 
Above table shows Thalassemic patients have lower levels of Red Blood Cells  (2.82 
X 10
6 
cmm) than Normal people ( Male: 4.5-6.5 X 10
6 
cmm and Female: 3.9-5.6 X 
10
6 
cmm) 
Table 11 
Prevalence of Blood Groups in Viral infected Thalassemic patients. 
1. For HIV infection 
Total Blood Group O Blood Group A Blood Group B Blood Group AB 
12 5 4 3 - 
100% 41.66% 33.33% 25.00% 0.0% 
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2. For  HBsAg infection 
Total Blood Group O Blood Group A Blood Group B Blood Group AB 
12 3 4 4 1 
100% 25.00% 33.33% 33.33% 8.33% 
 
3. For HCV infection 
Total Blood Group O Blood Group A Blood Group B Blood Group AB 
17 8 3 2 4 
100% 47.05% 17.64% 11.76% 23.52% 
 
There is no clear preference for any particular blood group in viral infected 
Thalassemic patients as number varies for each viral marker. 
However much higher prevalence of HCV in patients with blood group O  
 
Table 12 
Prevalence of Syphilis among Thalassemic Patients. 
Total Reactive  Non-Reactive 
218 00 218 
 
No seropositivity for Syphilis was observed in thalassemic patients. 
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CORRELATION ANALYSIS 
Correlation analysis of various parameters in hemogram as well as incidence of microbial infections with the amount of blood transfused was 
carried out.  
 
 Hb S.G.P.T. S.Iron RBC HCT MCV RDW-
CV 
WBC ml/year 
of blood 
HIV HBs
Ag 
HCV 
Hb 1            
S.G.P.T. 0.034 1           
S.Iron -0.228 0.001 1          
RBC 0.769 0.011 -0.183 1         
HCT 0.774 -0.019 -0.180 0.959 1        
MCV 0.134 -0.077 -0.033 0.118 0.378 1       
RDW-CV -0.152 -0.226 0.083 -0.023 0.050 0.175 1      
WBC 0.094 0.137 -0.057 0.078 0.115 0.116 0.152 1     
ml/year of 
blood 
-0.191 0.202 0.140 -0.066 -0.031 0.175 -0.057 -0.156 1    
HIV 0.023 0.065 -0.063 0.045 0.049 0.053 0.019 0.102 0.812 1   
HBsAg 0.004 0.292 0.125 0.058 0.023 0.047 0.033 0.123 0.634 0.239 1  
HCV 0.082 0.342 0.112 0.018 -0.062 0.038 0.013 0.149 0.725 0.596 0.412 1 
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As shown in the table there is a significant correlation between hemoglobin value, 
RBC count and hematocrit value. There was also a significant correlation of moderate 
degree between hematocrit value and mean corpuscles value. Significance was also 
observed between the amounts of blood transfused per year with viral infections. 
Significance was more with HIV infection followed by HCV and HBV infection. 
Moderate degree of significance was observed in between HIV and HBV infection as 
well as HIV and HCV infection. There was a low to moderate correlation between 
S.G.P.T. levels and Hepatitis Viral markers namely HBV and HCV. 
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Incidence of Microbial infection and co-relative data in Hemodialysis 
patients 
Male patients with autosomal dominant polycystic kidney disease (ADPKD) begin 
hemodialysis earlier than female patients. The rate of progression of many other renal 
diseases is also faster in men than women. 
                                                
Figure 15 
Gender wise distribution of patients on Hemodialysis 
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Figure 15 shows Gender wise distribution of patients on Hemodialysis. We have 
registered 115 total patients out of them 74 patients were of male gender and 41 
patients were females. Our results support literature data that males are more 
susceptible to kidney failure compare to females. 
 
Chronic Renal Failure patients on maintenance hemodialysis were distributed 
according to their age to observe prevalence of CRF in any particular age group. 
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Figure 16 
Age wise distribution of patients on Hemodialysis 
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Figure 16 shows distribution of hemodialysis patients according to their age. 3 
patients out of 115 were of below 19 yrs. 33 patients fall between 20-30 yrs. 28 
patients are between 31-40 yrs. 17 patients were between 41- 50 yrs. 16 patients were 
between 51-60 yrs. 11 patients were between 61-70 yrs. And only 7 patients were 
above 70 yrs.  
Almost 50% of the patients were in the age group of 20-40 years suggesting lower 
incidence of CRF in younger patients & relatively lower lifespan of these patients. 
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To observe the pattern of Blood Group distribution in Hemodialysis Patients the blood 
groups were determined. 
 
Figure 17 
Blood Group wise distribution of Patients on Hemodialysis 
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Total 115 % 
Blood Group A 29 24.94% 
Blood Group B 39 33.54% 
Blood Group O 34 29.24% 
Blood Group AB 13 11.18% 
 
Figure 17 shows Prevalence of Blood Group in patients on Hemodialysis Out of 115 
total patients 29(24.94%),39(33.54%),34(29.24%),13(11.18%) showed Blood Group 
A,B,O and AB respectively. Our result is in accordance with prevalence of blood 
group in general population suggesting no special linkage between blood group and 
CRF conditions. 
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Similarly Rh factor prevalence was determined in Hemodialysis patients. 
Figure 18 
Prevalence of Rh in patients on Hemodialysis 
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Figure 18 shows prevalence of Rh in patients on Hemodialysis. Out of 115 total 
patients 106 (91.16%) were Rh Positive and only 9 (7.74%) were Rh Negative.In 
accordance with the literature data Rh profile was observed in Hemodialysis patients. 
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Hemodialysis patients receive multiple blood transfusions over a long period of time. 
This makes them susceptible to various microbial infections much more than normal 
incidence. Frequency of incidence of viral markers was studied as follows. 
Figure 19 
Infectivity at the beginning of the study (2005) 
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Figure 19 shows infectivity at the beginning of study. At the beginning we have 
registered 115 patients out of them 35(30.43%), 07(6.08%), 0(0.00%) patients found 
HCV, HBsAg and HIV positive respectively. Total 42(36.52%)  patients out of 115 
having microbial infections in 2005.  An alarmingly high incidence of HCV was 
observed while HbsAg seropositivity was also observed comparatively high. 
Infectivity in CRF patients at the end of the study was also studied. 
 
 
 
103 
 
Figure 20 
Infectivity at the end of the study (2008) 
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Figure 20 shows infectivity at the end of study. At the end we have registered 170 
patients, out of them 68(40.00%), 12(7.05%) and 0(0.00%) patients were found HCV, 
HBsAg and HIV positive respectively. Total 80 (47.05%) patients out of 170 were 
having microbial infections in 2008. There was increased infectivity in HCV and 
HbsAg both viral markers. 
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Increased number of dialysis is suggestive of chronic illness of the patient. To observe 
the correlation between dialysis and infectivity following study was carried out. 
Figure 21 
Correlation between no. of Dialysis and HCV Positivity 
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 Average no. of Dialysis (%) 
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HCV Negative 45.58% 
 
Figure 21 clearly indicates that more the number of dialysis, (94.25% in HCV 
Positive patients and 45.58% in HCV Negative patients) more is the chance of 
infection by microbial agent. 
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There is a literature report that there may be correlation between Hepatitis infection 
and blood group. In our studies HCV infection was found in maximum number in 
Hemodialysis Patients.So prevalence of blood grouping in these patients was studied. 
 
Figure 22 
Prevalence of Blood Group in HCV infected patients on hemodialysis 
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Above graph shows prevalence of blood group in HCV Positive patients out of 68 
HCV infected patients 21,18,23 and 4 patients falls in blood group A,B,O and AB 
respectively. 
In contrast to the normal profile of general population blood group O was prominent 
followed by blood group A , B and AB in HCV infected hemodialysis patients. 
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Similarly prevalence of Rh factor in HCV infected hemodialysis patients was studied. 
 
Figure 23 
Prevalence of Rh Factor in HCV infected patients on hemodialysis 
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Figure 23 shows that out of 68 HCV positive patients 66(97.05%) patients are Rh 
Positive and only 2 (2.94%)of them are Rh Negative. Rh positive patients seem to be 
more prone to HCV infection compare to Rh negative patients. Since the number of 
patients is not sufficient for conclusively proving anything more patients need to be 
screened. 
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Malarial parasite may be transmitted through infective blood of the donor. However 
in rare cases patients receiving blood show positivity for malarial parasite. 
 
Figure 24 
Prevalence of Malarial Parasite among Hemodialysis Patients 
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Figure 24 shows positivity of malarial parasite (0.86%) in Hemodialysis patients and 
patient was found symptomatically suffering from P.falciparum after blood 
transfusion and so was the donor on follow up. 
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V.D.R.L. positivity among sera of Hemodialysis patients was studied to check the 
prevalence of Syphilis among Hemodialysis patients. 
 
Figure 25 
Prevlence of Syphilis samong Hemodialysed Patients 
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Figure 25 shows that no seropositivity for syphilis was observed. Spirochetes, the 
causative agent of Syphilis is a very fragile organism and cannot survive in stored 
blood for a longer period of time this could be possible reason for nonreactivity of the 
test. 
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Incidence of Microbial infection and co-relative data in Hemophilia 
patients 
Hemophilia a hereditary disorder of Coagulation results in deficiency of Factor VIII 
(Hemophilia A) or Factor IX (Hemophilia B) or rarely due to deficiency of other 
clotting factors. 
Figure 26 
Comparison of Various Factors among Hemophilic Patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26 explains Factor VIII deficiency was observed in 83% of patients while 14% 
patients were having deficiency of factor IX and 3% of patients were having 
deficiency of other factors such as factor V. Factor VIII deficiency is most commonly 
found among Hemophiliacs followed by deficiency of Factor IX and other factors. 
Sr.No. Factor MEMBERS NO. % 
1 VIII 193 83% 
2 IX 32 14% 
3 Others 07 3 % 
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Hemophilia is a chronic physical condition affecting the child from birth. Age group 
wise distribution was studied. 
 
Figure 27 
Age wise distribution of Hemophilic Patients 
 
 
 
 
 
 
 
 
 
 
Sr.no. Age group Members No. % 
1 0-5 year 17 08 
2 6-15 year 75 32 
3 16-30 year 103 44 
4 31 year 37 16 
 
Figure 27 includes majority of the hemophilia patients under present study belonged 
to age group between 16 and 30 followed by 6-15 years, above 31 years of age and 
least number of patients were in 0-5 year age group. This data suggests good prenatal 
counseling and efficient management of the disease in patients. 
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Hemophilia can be mild, moderate, or severe, depending on how much clotting factor 
is in the blood. We carried out factor estimation in order to establish severity of the 
disease. 
Figure 28 
Distribution of Hemophilic Patients according to Factor Level 
 
 
 
 
 
 
 
 
 
 
Sr. No. Factor Level Members No. % 
1 <1  95 40.94 % 
2 1-5 85 36.64% 
3 >5 52 22.42% 
 
Figure 28 shows Factor level in most hemophilia patients was found to be either 
below 1(40.94%) or between 1 and 5 (36.64%). There were 52 (22.42%) patients with 
factor level of more than 5. 
 
Majority of the patients under our study have severe hemophilia. 
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For the management of Hemophilia a patient needs to be transfused purified factor 
preparation or cryoprecipitated plasma. This increases the risk of transfusion 
transmitted infections. 
 
Figure 29 
Prevalence of Viral infections among Hemophilic Patients 
 
 
 
 
 
 
 
 
 
 
Sr.no. Positivity No. % 
1 HBS Positive 1 0.43 % 
2 HCV Positive 1 0.43 % 
3 HIV Positive 00 00 % 
 
 
Figure 29 shows that out of 232 patients, only 1 patient was found to be HBsAg and 1 
was HCV positive. All 115 patients were HIV negative. 
Because of the advanced procedures of inactivation of viruses such infections are less 
likely to occur. 
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Determination of Blood Group in Hemophiliacs was carried out as follows. 
Figure 30 
Prevalence of Blood Group in Hemophilics 
 
 
 
 
 
 
 
 
 
 
Figure 30 includes most prevalent blood group was B Positive followed by O 
Positive, It was closely followed by A Positive blood group and then it was AB 
Positive. As expected Rh negative blood groups were found comparatively less 
frequently. 
 
Sr.No. Blood Group Members No  
1 A Positive 64 27.58 
2 A Negative 03 1.29 
3 B Positive 71 30.61 
4 B Negative 04 1.72 
5 O Positive 66 28.45 
6 O Negative 10 4.31 
7 AB Positive 12 5.17 
8 AB Negative 02 0.86 
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Various socio-economic backgrounds of our patients were studied so that post-
effective therapy can be suggested. 
Figure 31 
Distribution according to their Family Income 
 
 
 
 
 
 
 
 
Sr No. Income Members No.  
1 <3000.00 Rs. 59 25 
2 3000.00-5000.00 Rs. 114 49 
3 5000.00-10000.00 Rs. 41 18 
4 >10,000 Rs. 17 8 
 
Figure 31 shows that 114 (49%) of the patients had an average family income of Rs. 
3000-5000. 59 (25%) patients had less then 3000 Rs. family income while 41(18%) 
had family income between 5000 and 10,000.17(8%) had family income of more then 
10,000 Rs. Since most of the patients come from lower middle income group factor 
replacement therapy could be a substantial burden compare to wet products. 
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Prevalence of CMV is common among general population  
Figure 32 
Prevalence of CMV among Multitransfused Hemophilic patients 
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Figure 32 shows that out of 232 patients we have studied 3 patients (1.29%) were 
found to be positive for CMV. 
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Incidence of Microbial infection and co-relative data in surgical multi 
transfused and leukemia patients 
 
Gender wise distribution of multitransfused surgical patients was studied. 
 
Figure 33 
Gender wise distribution of multitransfused surgical patients 
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Figure 33 shows out of 61 patients 38 multitransfused surgical patients are males and 
23 patients are females. 
Random selection of patients suggests that because of more outdoor activities male 
are more prone to surgical transfusions than females. 
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Age distribution pattern in surgical multitransfused patients was studied. 
 
Figure 34 
Age wise distribution of multitransfused surgical patients 
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Figure 34 shows age wise distribution of multitransfused surgical patients. There are 
total 61 patients out of them 12 patients are below 19 years, 34 patients are of 
between 20-30 yrs of age, 11 patients are of age between 31-40 yrs, 3 patients are of 
age between 41-50 yrs and only 1 patient is above 50 years and above. 
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Pattern of blood group prevalence was studied in our group of patients. 
 
Figure 35 
Blood Group wise distribution of multitransfused surgical patients 
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Figure 35 shows out of 61 patients 19 patients shows Blood Group A, 32 patients 
shows Blood Group B, 7 patients shows Blood Group O and only 3 patients shows 
blood group AB. 
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Following results show distribution of Rh factor among multitransfused surgical 
patients.  
 
Figure 36 
Prevalence of Rh factor among multitransfused surgical patients 
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Figure 36 shows prevalence of Rh factor out of 61 patients 52 patients are Rh Positive 
and only 9 patients shows Rh Negative factor. Incidence of Rh negative patients is 
somewhat higher than literature data. 
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As a case study blood samples of surgical multitransfused patients were checked for 
bacterial growth to study incidence of bacteremia due to blood transfusion. 
 
 
Figure 37 
Blood Culture data of multitransfused surgical patients 
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Figure 37 shows out of 61 blood cultures no positive blood cultures were reported, 4 
contaminants were isolated form 61 samples. 
Generally patients are given stored blood and surgical patients are on broad spectrum 
antibiotics. Due to these reasons bacteraemia is extremely rare. 
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Occurance of viral infection among our study group was checked. 
 
Figure 38 
Infectivity rate among multitransfused surgical patients 
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Figure 38 shows out of 61 patients 1 patient was HCV Positive, 2 patients were 
HBsAg Positive and none of them show HIV positive result. s 
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Gender wise sdistribution of multitransfused leukemic patients was studied to check 
its prevalence in any particular gender. 
 
Figure 39 
Gender wise distribution of multitransfused Leukemic patients 
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Figure 39 shows gender wise distribution of leukemic patients. Total 10 patients we 
have registered out of them 7 patients were male and 3 patients were females. 
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Age wise distribution of Leukemic patients was studied. 
 
Figure 40 
Age wise distribution of Leukemic patients 
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Figure 40 shows out of 10 leukemic patients, 8 patients fall between 0-19 yrs and 2 
patients fall between 20-30 years. 
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Determination of Blood Group in Multitransfused Leukemics was carried out as 
follows. 
 
Figure 41 
Prevalence of Blood Group among multitransfused Leukemic patients 
 
 
Total No. % 
Blood Group A 02 20% 
Blood Group B 05 50% 
Blood Group O 03 30% 
Blood Group AB 00 00% 
 
Figure 41 shows prevalence of Blood Group in accordance with literature reports. 
Blood Group B was the most prominent(50%) followed by Blood Group O(30%), 
Blood Group A (20%).There is higher prevalence of Blood Group B as compared to 
the normal population. As the number of subjects under the study is less, no 
conclusive remark can be made. 
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Rh Factor distribution was observed as follows in our study. 
 
Figure 42 
Prevalence of Rh Factor among multitransfused Leukemic patients 
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Figure 42 shows prevalence of Rh factor in leukemic patients out of 10 patients 9 
patients shows Rh Positive factor and 1 patient shows Rh Negative factor.  
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Leukemia is a disease which requires intense and prolonged treatment which may be 
very expensive. In order to study socio-economic impact of the disease following 
study was carried out. 
Figure 43 
Distribution of Leukemic patients according to their family Income 
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Figure 43 shows family income per month of multitransfused Leukemic patients. Out 
of 10 patients we have registered 1 patient shows income <3000.00 Rs. 1 patient 
shows income between 3000-5000 Rs. And 2 patients show family income between 
5000-10000 Rs. And 6 patients show family income more than 10000 Rs. 
Patients having monthly income of less than Rs. 10,000 (40%) have to bear burden of 
treatment of Leukemia with great difficulty as per our study. 
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Rate of infectivity of viral markers namely HCV, HbsAg and HIV were studied in our 
subjects. 
                           
Figure 44 
Infectivity rate of multitransfused leukemic patients 
 
 
Total no. of patients HCV HBsAg HIV 
10 00 00 00 
 
 
Figure 44 shows infectivity rate among Leukemic patients. All ten patients were HIV, 
HBsAg and HCV negative. 
Fortunately none of our subjects had additional complication of life threatening viral 
infections due to multiple blood transfusions. 
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Cytomegalovirus infection is common among Leukemic patients. Seropositivity of 
Leukemic patients for CMV was studied in our subjects. 
 
Figure 45 
Prevalence of CMV among Multitransfused Leukemic patients 
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Figure 45 shows infectivity rate of CMV among Leukemic patients. Out of ten 
patients three (30%) were CMV Positive. CMV infection is common among 
immunocompromised individuals. Chemotherapy treatments in Leukemia patients 
result in poor immune status of these patients. Our results indicate CMV infection 
may be due to immunocompromised status of our subjects. 
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Figure 45 
Comparative Data 
 
0.00%
5.00%
10.00%
15.00%
20.00%
25.00%
30.00%
35.00%
40.00%
Co
nt
ro
l
Th
al
as
se
m
ic
He
m
od
ia
ly
sis
Su
rg
ica
l
Le
uk
em
ic
HI
V
HB
sA
g
HC
V
HIV
HBsAg
HCV
 
Viral 
Infections 
Control 
(%) 
Thalassemia 
(%) 
Hemodialysis 
(%) 
Hemophilia 
(%) 
Surgical 
(%) 
Leukemic 
(%) 
HIV 0.55% 5.04% - - 0.00% - 
HBsAg 1.71% 3.66% 7.05% 0.43% 3.28% - 
HCV 0.87% 8.25% 40.00% 0.43% 1.64% - 
 
Figure 45 shows comparative incidence of viral markers in all five cohorts as 
compared to the control population of healthy donors. 
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Comparative aspect of viral infections in different cohorts of multitransfused patients 
is studied. 
 
Figure 46 
Comparative incidence of viral infections in various cohorts of multitransfused 
patients 
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Figure 46 shows overall comparison of viral infections in different cohorts. 
Prevalence of HIV among Thalassemic patients,Hemophilics,Hemodialysed patients, 
surgical patients and Leukemia patients is 5.04%,0.00%,0.00%,0.00% and 0.00% 
respectively. Prevalence of HBsAg among Thalassemic patients, Hemophilics, 
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Hemodialysed patients, surgical patients and Leukemia patients is 
3.66%,0.43%,7.05%,3.28% and 0.00% respectively. Prevalence of HCV among 
Thalassemic patients,Hemophilics,Hemodialysed patients, surgical patients and 
Leukemia patients is 8.25%,0.43%,40.00%,1.64% and 0.00% respectively. . 
Prevalence of CMV among Thalassemia patients,Hemophilics,Hemodialysed patients, 
surgical patients and Leukemic patients is 0.00%,2.64%,0.00%,0.00% and 30.00% 
respectively.  
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CHAPTER 5 
DISCUSSION 
 
Blood transfusion currently faces interesting challenges. While advances have been 
dramatic, both in terms of technology and organizational up gradation in developed 
countries, blood transfusion in developing countries still tend to stagnate with acute 
shortages, lack of component therapy and safety problems. 
 
Many a times, these problems are perpetuated by financial limitations, political 
instability, endemic infections transmitted by transfusion and cultural taboos which 
inhibit blood donation. The net effect is that blood transfusion takes place in 
dangerous conditions, its lifesaving purpose subverted by lack of effective control. 
Microbial adaptation, climate and weather changes, war and famine, and the spectre 
of bioterrorism all raise the concern of emerging infectious threat to the blood supply. 
The situation has been further compounded and thus demands urgency with the 
emergence of AIDS and the growing understanding of the complexity of Hepatitis and 
its threat to transfusion recipient. Some infectious agents e.g. cytomegalovirus, human 
T-lymphotropic virus, Treponema pallidum are transfused more readily by relatively 
fresh blood components, whereas other agents (HBV, HIV) are stable in stored, and 
even in frozen red cells or plasma. 
 
As far as transfusion transmitted infections are concerned in patients receiving 
multiple blood /blood components it depends on the demographic epidemiology of the 
etiological agent as well as socioeconomic factors associated with treatment. 
 
Our present study is an attempt to highlight prevalence of some transfusion 
transmitted infections in and around Rajkot and compare it with available literature 
data in multiple blood transfusion individuals. 
 
Source of transfusion transmitted microbial infection in various cohorts of 
multitransfused patients is ultimately donor’s blood. In our studies incidence of 
microbial infections in donors were examined to get the idea of frequency as well as 
demographical variation of these microbial markers in the population. 
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HBsAg seropositivity in Donors 
No. Author Year Place Positivity % 
1 Talib et al 1983 Delhi 17.70% 
2 Shanmugham et al 1978 Kerala 9.60% 
3 Dutta & Mohammed 1972 Delhi 2.65% 
4 Tejsingh Thakur 1990 Himachal Pradesh 2.56% 
5 Pal et al 1973 Chandigadh 2.20% 
6 Elvina et al 1989 Mumbai 2.02% 
7 Vipul Khakhar 2002 Jamnagar 1.67% 
8 Thaygarajan S.P. 1981 Himachal Pradesh 1.62% 
9 Sama et al 1973 Delhi 1.60% 
10 Graves & Biswas 1973 Calcutta 0.40% 
11 Present Study 2007 Rajkot 1.98% 
 
 
Hepatitis B virus infection is a major cause of morbidity and mortality in humans and 
it is endemic all over the world. About 350 million people of the world are infected 
with this virus (Lee, 1997) 
 
Hepatitis B virus is major cause of chronic hepatitis, cirrhosis and hepatocellular 
carcinoma especially in Asian countries. Due to crowded and unhygienic living 
conditions, horizontal transmission in early childhood is the major mode of infection 
of HBV in India (Tandon et al., 1996). 
 
Hepatitis C virus first identified in 1989, was major cause of non-A, non-B hepatitis. 
Around 100 million people worldwide are estimated to be infected with HCV. 
Chronicity occurs in about 80% of infected patients. The health burden of chronic 
hepatitis C infection in the western world is gradually being realized. In most Asian 
countries, Hepatitis B virus is still the major cause of chronic liver disease and 
hepatocellular carcinoma. In Japan, the pattern is changing in the past decades and 
now HCV is the predominant cause of HCC. A comprehensive assessment of HCV 
infection in Asia is important. Any factor or activity that increases the risk of 
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transmission must be identified and built into strategy for infection control. This is 
particularly vital when effective HCV vaccine is not available. 
 
 HCV seropositivity in Donors 
 
No. Author Year Place No. 
Tested 
Positivity % 
1 Khan M.  1993 Dhaka 163 2.4% 
2 Panigrahi A.K. 1997 Delhi 15922 1.85% 
3 Kakaepoto G.N. 1996 Karachi Pakistan 16704 1.80% 
4 Jaiswal S.P. 1996 Indore 280 1.78% 
5 Irshad M. 1995 Delhi 234 1.54% 
6 DeSilva H.J. 1998 Sri Lanka 1748 0.74% 
7 Choudhury N. 1995 Lucknow 313 0.30% 
8 Jha J. 1995 Pune NA 0.25% 
9 Present Study 2008 Rajkot, India 7458 1.09.% 
 
 
Hepatitis C Virus has been identified as an important etiological agent responsible for 
transfusion associated hepatitis and accounts for about fifty percent of the sporadic 
cases of non-A, non-B hepatitis (CDC, 1991). 
  
The transmission of human immunodeficiency virus (HIV) through blood transfusion 
and the consequent emergence of transfusion associated acquired immune deficiency 
syndrome (AIDS) epidemic have arguably transformed the field of transfusion 
medicine over past several decades. HIV-1 and HIV-2 are the etiologic agents. The 
rate of confirmed positive infections detected amongst blood donors declined 
markedly due to notification and deferral of repeat donations from individuals, who 
had tested positive and with implementation of better strategies (donor informational 
documents and donor questionnaires) to exclude "at risk donors". 
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HIV seropositivity in Donors 
No. Author Year Place No. Tested Positivity % 
1 Kwesigabo G. 2002 Tanzania 454 11.90% 
2 Kiwanuk N. 2002 Uganda 6868 3.92% 
3 Durosinmi M.A. 2002 Nigeria 16080 2.30% 
4 Tallur S. 1997        Hubli 19705 1.74% 
5 Rao P. 1994 Pune 44190 0.69% 
6 Chandra M. 1991 Bombay 30632 0.60% 
7 Sombasiva Rao R. 1995 Pondichary 19023 0.55% 
8 Kulshreshtha R. 1999 Lucknow 39965 0.53% 
9 Yan Y, Zhengz 1999 Fiji 569873 0.12% 
10 Chievetta J.A. 2001 Canada 2000000 0.10% 
11 Bhushan et al 1993 Vellore 79591 0.10% 
12 Present Study 2008 Rajkot, India 7458 0.96% 
 
Recognition of a possible relationship between blood transfusions and the AIDS 
provided early clues that AIDS might have an infectious cause. In much of Asia and 
Africa, the transmission of HIV by blood transfusion is still an important source of 
infection. Reasons for high rate of transmission, include 1) high demands for blood 2) 
prevalence of HIV infection amongst donor population and 3) The fact that HIV 
infection is not confined to a minority of the population who can be requested to 
refrain from blood donation and 4) the inability of many laboratories to test for HIV 
or to perform and control the tests properly. As can be seen from the table some of the 
African countries like Tanzania has a very high prevalence of HIV among donors 
whereas in India seropositivity is variable in different regions of the country 
depending upon socio-cultural activities.   
 
Hepatitis B is an infection of major public health importance. More than one third of 
world’s population has been infected with Hepatitis B virus (Sarin, 2002).  
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HBsAg seropositivity in Thalassemic patients 
No. Author Year Place No. Tested Positivity % 
1 Hwang K.C. 1990 China 68 82.4% 
2 Juneja M. 1998 New Delhi 64 31% 
3 Moroni G.A. 1984 Italy 128 25% 
4 Mollah A.H. 2003 Dhaka 152 13.8% 
5 Cacopardo B. 1992 Italy 152 8% 
6 Williams T.M. 1992 London 54 7.4% 
7 Khakhar V. 2006 Surendranagar,Gujarat 90 6.6% 
8 Singh H. 2003 Lucknow 70 5.7% 
9 Chakravarti A. 2005 New Delhi 50 2.0% 
10 Mirmomen S. 2006 Shiraz, Iran 732 1.5% 
11 Karimi M. 2001 Shiraz, Iran 755 0.53% 
12 Present Study 2008 Rajkot, India 218 3.66% 
 
The frequency and natural history of Hepatitis B virus infection vary with geographic 
regions. A correlation study of literature data and our results suggested that Hepatitis 
B seropositivity in the Thalassemic subjects under this study was not alarmingly high. 
Though it was higher compare to data from Iran and Northen India, it is much less in 
comparison to China.  
 
Hepatitis C virus has affected 150 million people worldwide and the number is 
increasing to term the disease as one of the most deadly disease of the century.  
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HCV seropositivity in Thalassemic patients 
No. Author Year Place No. Tested Positivity % 
1 Silipoulou I. 1995 Greece 24 91.6% 
2 Locasciulli A. 1993 Monza,Italy 25 76.0% 
3 Angelucci E. 1994 Pesaro, Italy 256 60% 
4 Chakravarti A. 2005 New Delhi 50 60% 
5 Cocopardo B. 1992 Italy 152 47% 
6  Kazemi M. 2008 Rafsanjan, Iran 60 45% 
7 Nigro G. 1992 Rome, Italy 36 41% 
8 Wonke B. 1990 London 73 23.3% 
9 Juneja M. 1998 New Delhi 64 21% 
10 Singh H. 2003 Lucknow 70 20.0% 
11 Mirmomen S. 2006 Iran 732 19.3% 
12 Agrawal M.B. 1993 Mumbai 72 16.7% 
13 Karimi M. 2001 Shiraz, Iran 466 15.7% 
14 Mollah A.H. 2003 Dhaka 152 12.5% 
15 Williams T.M. 1992 London 54 11.1% 
16 Samimi-Rad K. 2007 Tehran, Iran 98 5.1% 
17 Present Study 2008 Rajkot, India 218 8.25% 
 
Individuals with chronic hepatitis C are at much higher risk of developing 
hepatocellular carcinoma. The incidence of HCC is on an increasing trend in many 
parts of the world. The possible routes of transmission include the use of unscreened 
blood, blood products, tissue or organs, inadequately sterilized equipments etc. (Sarin, 
2002b) 
 
Seroprevalence of anti-HCV worldwide and in India showed substantial variation as 
can be seen from the comparative data. 
HIV is a serious disorder of immune system makes the most vulnerable to a host of 
life threatening infections including unusual malignancies. A watchful WHO 
publishes data on spread of infection across the globe. According to them virtually 
every country is in the grip of this deadly disease and the epidemic is out of control in 
many places. 
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HIV seropositivity in Thalassemic patients 
No. Author Year No. Tested Positivity % 
1 Dubey A.P. et al. 1993 75 9.3% 
2 Sen S.  et al. 1993 203 8.9% 
3 Vohra R. 1995 89 8.9% 
4 Khan M.A. 1992 203 8.37% 
5 Bichile S.K.  et al. 1992 50 6.0% 
6 Sudarshan et al. 1994 223 3.5% 
7 Amrapurkar D.N. et al. 1992 40 2.5% 
8 Hazami M.A.F.E.L. et al. 1989 212 2.35% 
9 Sur D. Chakraborty AK. 1990 330 0.9% 
10 Bhargava M. et al. 1991 185 0.54% 
11 Singh S. et al. 1993 100 0.0% 
12 Choudhary V.P.  et al. 1993 91 0.0% 
13 Chandra  S.  et al. 1993 22 0.0% 
14 Choudhary N. et al. 1995 19 0.0% 
15 Mirmomen S. 2006 732 0.0% 
16 Present Study 2008 218 5.04% 
 
Increasingly the spotlight is on the spread of HIV through the Asian continent, 
specially in South Asia and East Asia while rates remain low relative to some other 
regions, well over 7 million Asians are already infected and HIV is clearly beginning 
to spread in earnest through the vast populations of India and China ( HIV testing 
manual). 
 
Incidence of HIV in multitransfused Thalassemic patients in our study was higher 
than a few studies carried out by other workers. However, incidence as high as 9.3% 
has been reported by other group of workers. Our results show a moderate rate of HIV 
incidence.  
 
Patients of Hemophilia receive various blood components upon episodes of bleeding. 
Depending upon the infrastructure and socio-economical background, the patient may 
receive purified factor preparation to fresh frozen plasma (FFP). Incidence of 
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microbial infection depends on the component given to the patient as well as viral 
inactivation procedure followed. 
 
HBsAg Seropositivity in Hemophilic patients 
No. Author Year Place  No. Tested Positivity % 
1 Nebbia G. 1986 Milan, Italy 44 55% 
2 Sengupta B. 1992 Calcutta 37 24.3% 
3 Chow M.P. 1991 Taiwan 11 9% 
4 Ghosh K. 2000 ICMR, Mumbai 400 6% 
5 Sharifi-mood B. 2007 Iran 81 4.9% 
6 Present Study 2008 Rajkot, India 232 0.43% 
 
 
As shown in above table there is a great variation from different study group not only 
in the percentage positivity but also the size of the sample. In our present study Rajkot 
Chapter of National Hemophilia Society receives FFP from a selected pool of donors 
carefully screened and restricted only for this purpose. This explains low 
seropositivity of Hepatitis B marker in our study. The reason for low seropositivity 
can be attributed to vaccination against Hepatitis B to all our Hemophiliac subjects. 
 
Prevalence of HCV among Hemophiliacs depends primarily upon the amount and 
type of product transfused. Almost universal exposure to HCV is observed in 
Hemophiliacs receiving untreated commercial clotting factor concentrates. However, 
Hemophiliacs receiving appropriately inactivated coagulation components from single 
donor cryoprecipitate generally remain Anti-HCV negative (Brettler, 1990). 
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HCV Seropositivity in Hemophilic patients 
No. Author Year Place No. Tested Positivity 
% 
1 Chow M.P. 1991 Taiwan 11 100% 
2 Ghany M.G. 1996 Louisiana, USA 100 79% 
3 Samimi-Rad K. 2007 Tehran, Iran 76 43.4% 
4 Sharifi-mood B. 2007 Iran 81 29.6% 
5 Sengupta B. 1992 Calcutta 37 27% 
6 Ghosh K. 2000 ICMR, Mumbai 400 23.9% 
7 Present Study 2008 Rajkot, India 232 0.43% 
 
HCV seropositivity in hemophilic patients found to be varying from 100% to 0.43% 
in various studies. As explained earlier policy of giving single donor cryoprecipitate 
to hemophiliacs is the reason of low seropositivity in our study. 
 
Because of the enormous risk involved in transmission of HIV through blood, safety 
of blood and blood product is of paramount importance. Currently, the risk of 
transmission of HIV through transfusion is minimal, because effective preventive 
strategies, including new laboratory tests, have been implemented.  
 
HIV Seropositivity in Hemophilic patients 
No. Author Year Place No. Tested Positivity % 
1 Chow M.P. 1991 Taiwan 11 82% 
2 Sultan Y. 1987 Paris, France 2049 48% 
3 Ghany M.G. 1996 Louisiana, USA 100 42% 
4 Sengupta B. 1992 Calcutta 37 24.3% 
5 Ghosh K. 2000 ICMR, Mumbai 400 3.8% 
6 Present Study 2008 Rajkot, India 232 00.00% 
The virus that causes AIDS (HIV) can be carried in clotting factors as well as plasma. 
However, there has been no documented case of these viruses being transmitted 
during replacement therapy in our present study. Transmission of viruses has been 
prevented by careful screening of blood donors, testing of donated blood products, 
treating donated blood products with a detergent and heat to destroy viruses. 
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Infectious agents like Cytomegalovirus are transmitted more readily by relatively 
fresh blood components. The transmission of CMV by blood transfusion was first 
reported in the 1960s (Klemola et al., 1969). In most cases CMV appears to be 
transmitted only by cellular blood components, and the virus reactivates from donor 
leucocytes after transfusion. Host as well as donor factors are involved in CMV 
infection.                                  
CMV Seropositivity in Hemophilic patients 
No. Author Year Place No. Tested Positivity % 
1 Okubo S. 1990 Japan 49 85.70% 
2 Rollang H. 1989 Norway 377 75.00% 
3 Rabkin C.S. 1993 Rockville 393 49.00% 
4 Chesseman S.H. 1984 NA 100 42.00% 
5 Nogueira E. 2000 Brazil 100 25.00% 
6 Present study 2008 Rajkot, India 232 01.29% 
 
Generally, the line of treatment in Hemophiliac patients after the episodes of bleeding 
is either FFP or pure commercially available clotting factors. Leucodepletion in both 
these cases reduce the chances of acquiring CMV infection. However, improper 
preparation may account for low incidence as reported in our study. 
 
The incidence of post-transfusion Hepatitis B throughout the region has reduced 
tremendously after introduction of HBsAg screening of donor blood in most 
countries.                
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HBsAg Seropositivity in Patients on Hemodialysis 
No. Author Year Place No. Tested  Positivity % 
1 Aghanishinikar P.N. 1992 Sultanate Of 
Oman 
102 52% 
2 Barton E.N. 1998 Jamaica 63 34.9% 
3 Al-Mugeiren M.  Riyadh 20 15% 
4 Hmida S. 1995 Tunisie 235 8% 
5 Ballester J.M. 2005 Havana, Cuba  318 5.3% 
6 Jaffers L.J. et al 1990 California 90 1.11% 
7 Present Study 2008 Rajkot, India 115 7.05% 
 
Viral liver diseases, especially due to hepatitis B virus (HBV) and hepatitis C virus 
(HCV), were observed with a high frequency in hemodialysis units throughout the 
world. Due to the deficient immune response of uremic subjects, which renders them 
unable to eliminate viruses, hemodialysis patients act as reservoirs of the viruses and 
transmit infection to other patients, to the dialysis unit staff and eventually to their 
own family, in the case of infection with HBV. 
 
Hepatitis C virus (HCV) infection is a global health problem, common worldwide, 
leading to acute and chronic hepatitis and its consequences of hepatocirrhosis and 
hepatocellular carcinoma. Patients on hemodialysis belong to the high-risk group of 
HCV infection. The prevalence of HCV infection in dialysis patients ranges from 4% 
to more than 70% in some countries. The main reasons for such a high incidence of 
infections are a high prevalence of HCV infection in the general population, lack of 
standard infection precautions and effective vaccination, inadequate disinfection 
procedures of dialysis machines and other medical equipment, as well as spread of 
infection from patient to patient, especially in dialytic centers with a high percentage 
of infected patients. The diagnostic procedures useful in the evaluation of HCV 
infection are detection of anti-HCV antibodies. 
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HCV Seropositivity in Patients on Hemodialysis 
No. Author Year Place No. Tested  Positivity % 
1 Capsa D. 1991 Romania 133 91.7% 
2 Gohar S.A. 1995 Ain-shams 46 87.5% 
3 Ballester J.M. 2005 Havana, Cuba  318 51.6% 
4 Hmida S. 1995 Tunisie 235 45.10% 
5 Al-Mugeiren M. 1992 Riyadh 20 45% 
6 Al-furayh O. 1992 Riyadh 52 40.4% 
7 Wu J.S. 1991 Taiwan 63 36.5% 
8 Jaffers L.J. et al 1990 California 90 12% 
9 Barton E.N. 1998 Jamaica 63 7.9% 
10 Present Study 2008 Rajkot,India 115 40.00% 
 
As can be seen from the table patients undergoing maintenance hemodialysis 
constitute an especially important high risk group for HCV acquisition. Overall, Anti-
HCV positivity among donors is not significantly high and therefore, blood 
transfusion alone does not seem to be responsible for the majority of HCV infections 
among the dialysis patients. Taking into consideration well documented evidence of 
role of poor infection control practices in HCV transmission among dialysis patients, 
dialysis units need to evolve stricter protocols for eliminating this mode of the spread 
of virus (Lamballerie, 1996). 
 
In India, the main mode of transmission of HIV is through sexual contact. However, 
HIV infected blood/blood products can also transmit this infection. This is the most 
efficient way of transmission of HIV. Even a small transfusion of infected blood 
results in virtually 100% seroconversion.  Many social and economic factors play role 
in incidence of AIDS in different part of the world ranging from low literacy to unsafe 
sex to alcohol use (HIV testing manual b). 
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HIV Seropositivity in Patients on Hemodialysis 
No. Author Year Place No. Tested  Positivity % 
1 Barton E.N. 1998 Jamaica 63 9.5% 
2 Aghanishinikar P.N. 1992 Sultanate Of 
Oman 
102 2.0% 
3 Assogba U. 1998 Paris 347 1.1% 
4 Ballester J.M. 2005 Havana, Cuba  318 00.00% 
5 Hmida S. 1995 Tunisie 235 00.00% 
6 Al-Mugeiren M.  Riyadh 20 00.00% 
7 Present Study 2008 Rajkot, India  115 00.00% 
 
Although each donated unit of blood is tested for evidence of infection by specific 
agents, there are at least four potential reasons why transmission of these agents may 
still occur: a) the donor has negative laboratory test results during the early stages of 
infection, known as the window period, b) the existence of a chronic carrier state in 
which a clinically asymptomatic donor will persistently test negative on a screening 
assay, c) donors harboring a mutant or atypical variant and d) laboratory errors when 
performing the screening tests. Measures to assure the safety of blood and blood 
components include use of voluntary donors, donor selection and questioning, 
laboratory testing for serological markers of infections, maintenance of registries of 
disqualified donors. 
 
HBsAg Seropositivity in Multitransfused Surgical Patients 
No. Author Year Place No. Tested  Positivity % 
1 Utkan A. 2006 Turkey 646 2.50% 
2 Ganczak M. 2008 Poland 100 1.00% 
3 Present study 2008 Rajkot, India 61 3.28% 
 
High incidence of Hepatitis B infection in our study compare to the available 
literature data may be attributed to low sample size and general reliability on 
replacement donors in surgical cases. 
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HCV infections continue to be a source of clinical interest resource utilization for the 
near future. It is highly likely that a marked increase in the prevalence of hepatic 
cancer will be the next most common disease associated with chronic hepatitis C. 
Thus, research directed at preventing and treating HCV infection, therapies aimed at 
blunting the antigenic effect of HCV and treating HCV induced hepatic cancer should 
be initiated and pursued aggressively. As HCV may soon account for more deaths 
annually than are due to HIV infections, it is essential to identify mechanisms of HCV 
virulence, persistence and oncogenicity. Only with such information will it be 
possible to ease the disease burden due to this rather single and complex infectious 
agent. 
 
HCV Seropositivity in Multitransfused Surgical Patients 
No. Author Year Place No. Tested  Positivity % 
1 Utkan A. 2006 Turkey 646 0.60% 
2 Ganczak M. 2008 Polish 100 0.00% 
3 Present study 2008 Rajkot, India 61 1.64% 
 
Similar to the results obtained with HBV infections there was higher prevalence of 
HCV infection among our subjects compared to the literature study.  
 
Because HIV is both cell associated and present in plasma, all blood components are 
potentially infectious. The virus is well preserved in refrigerated and frozen blood; 
however, components that are washed, leucoreduced or cold stored for several weeks, 
procedures that diminish the number of viable leucocytes or the amount of virus 
reduced the likelihood of transfusion transmission (Donegan et al.1990). 
 
HIV Seropositivity in Multitransfused Surgical Patients 
No. Author Year Place No. Tested  Positivity % 
1 Utkan A. 2006 Turkey 646 0.00% 
2 Ganczak M. 2008 Polish 100 0.00% 
3 Present study 2008 Rajkot, India 61 0.00% 
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The reduction in risk of transfusion transmitted HIV over the past fifteen years has 
been dramatic and reassuring. Donor demographics have proved effective at 
identifying and excluding donors at high risk for infection and transmission of HIV. 
 
Platelet rich plasma and platelet concentrates are indicated in Leukemia. Post 
transfusion hepatitis in leukemia patients is not very frequent since the patients are 
vaccinated against this virus. 
 
HBsAg Seropositivity in Multitransfused Leukemic Patients 
No. Author Year Place No. 
Tested  
Positivity % 
1 Tavil B. 2007 Turkey 160 15.00% 
2 Yeo W. 2000 China 626 12.00% 
3 Kebudi R. 2000 Istanbul 50 10.00% 
4 Rossi D. 2009 Italy 173 10.00% 
5 Monteleone P.M. 1994 Massachusetts 45 00.00% 
6 Present Study 2008 Rajkot, India 10 00.00% 
 
 
As the sample size in present study was not large enough, no concrete conclusion can 
be made about the incidence of HBsAg seropositivity in multitransfused Leukemia 
patients. However, literature studies as shown on in the table show the incidence up to 
15%. 
 
Hepatitis C infection is considered to be the most common transfusion transmitted 
infection in the developed world. At present, only testing for Hepatitis C antibody is 
routinely employed. The antibody to the hepatitis C virus appears 54-192 days in a 
person’s blood after infection. If an infected person donates blood prior to the 
appearance to this antibody the chance of that blood being used in a transfusion is said 
to 1 out of 103,000 donations. 
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HCV Seropositivity in Multitransfused Leukemic Patients 
No. Author Year Place No. 
Tested  
Positivity % 
1 Kolho E. 1993 Finland 49 24.50% 
2 Kebudi R. 2000 Istambul 50 14.00% 
3 Monteleone P.M. 1994 Massachusetts 45 8.90% 
4 Gharagozloo S. 2001 Iran 23 4.30% 
5 Tavil B. 2007 Turkey 160 1.90% 
6 Brodine S.K. 1995 California 2875 0.20% 
7 Locasciulli A. 1994 Italy 15 00.00% 
8 Present Study 2008 Rajkot, India 10 00.00% 
 
It appears that due to the implementation of new epitopes of viral antigens in third 
generation ELISA it has become safer to the patient to rule out HCV infection. 
Present study does not have any positive report for this marker. 
 
Risk of transmission of HIV after p24 antigen screening in donor’s blood in 
developed countries has decreased the risk of transmission very drastically. Even in 
developing countries like India awareness about HIV status has reduced incidence of 
transfusion transmission of HIV. 
 
HIV Seropositivity in Multitransfused Leukemic Patients 
No. Author Year Place No. 
Tested  
Positivity % 
1 Kebudi R. 2000 Istambul 50 00.00% 
2 Monteleone P.M. 1994 Massachusetts 45 00.00% 
3 Present Study 2008 Rajkot, India 10 00.00% 
 
Present study matches with that of literature data of 0% seropositivity for HIV marker 
in multitransfused Leukemia patients. 
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Subjects at higher risk of severe primary CMV infection are those who are anti-CMV 
negative patients with impaired immunity. Unfortunately, most of the Leukemic 
patients fall into this category. Transfusion transmitted cytomegalovirus infection 
(TT-CMV) has been documented as a cause of significant morbidity and mortality in 
immunocompromised as well as immunocompetent recipients. Window period 
infections are the most likely source of antibody screening failures. 
 
CMV Seropositivity in Multitransfused Leukemic Patients 
No. Author Year Place No. Tested  Positivity % 
1 Vinelli E. NA Honduras 100 43.00% 
2 Present 
Study 
2008 Rajkot, India 10 30.00% 
 
During the past decade major advances have been achieved regarding the 
management of CMV infection through the development of new diagnostic 
techniques for the detection of the virus. Nevertheless, in immunosupressed patients, 
CMV infection still causes severe disease that could be fatal.  
 
From the above comparative data it can be said that: 
 
- There is increasing incidence of sero-positivity of viral markers in donors over the 
years. This suggested that donation in the window period of infection or technical 
and demographical limitation of a developing country such as India. 
- Except for hepatitis B marker in thalassamic patients, there was significant rise in 
viral markers in thalassamic as well as hemo-dialysis patients at the end of the 
study.  
- As compared with the initial sero-positivity for HCV marker in hemo dialysis 
patients, there was a sharp increase at the end of the study. Medical fraternity 
seriously needs to look at the entire process of treatment to prevent renal failure 
patients acquiring HCV infection.  
- Incidence of CMV sero-positivity was observed in hemophilia and leukemia 
patients. Later being immunocompromised, it was expected that opportunistic 
pathogen like CMV may lead to secondary complications. 
149 
 
- Incidence of post transfusion parasitic infection by Plasmodium falciparum was 
noted in one hemodialysis patient. 
- With reference to HBV and HCV infection in hemophilia patients policy of 
strictly adhering to selected donors for fresh frozen plasma and using high quality 
viral inactivated clotting factors seem to be the cause of low incidence of sero-
positivity in these patients. 
- Survey of any particular blood group having predilection for HCV infection in 
moderately sizable population of HCV sero-positive patients show that blood 
group O people were most affected followed by blood group A patients.   
- Socio economic parameters reflected that the burden of costly treatment was 
mainly on lower middle income group of people.  
- Children in the age group below 19 years maximally reflected higher incidence of 
leukemia as per the available literature data. 
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CHAPTER 6 
SUMMARY 
Blood transfusion is a routine life saving regime for millions worldwide. It is like a 
double edged sword which if not used with discretion and technical expertise can lead 
to many undesirable after events. Sudden spurt of awakening to the issue of blood 
safety arise only and when there is mass morbidity or mortality.  
 
Certain medical conditions require that blood be transfused to patients on a regular 
basis over a period of months or years. Due to repeated transfusion of blood such 
individuals are at higher risk of complications related to blood transfusion. 
 
Variety of factors ranging from window period of infection in donors to negligence in 
part of blood handlers to lack of infrastructure, rate of microbial infection due to 
blood transfusion is higher in developing countries like India. 
 
Present research was carried out to study incidence of microbial infections in various 
cohort of patients who receive multiple blood transfusion. 
 
Data of blood donation pattern and prevalence of microbial infection in “supposedly” 
healthy donors was studied to obtain insight into the quality of blood received by 
these patients. 
 
Patients receiving multiple blood transfusion or blood component on regular basis 
were divided into four categories: 
(1) Thalassaemia patients 
(2) Hemodialysis patients 
(3) Hemophilia patients 
(4) Surgical multi transfused and leukemia patients    
 
Various parameters were studied in each group such as: 
 Socio economic parameter in which patients were categorized on basis of their 
age, gender, caste and family income.        
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 Hematological parameters like hemoglobin level and haemogram which 
included WBC, RBC, HCT, MCV and RDW-CV. 
 Serological parameters like detection of viral markers e.g. HIV, HBsAg, HCV 
and CMV by ELISA method and detection of Treponema pallidum infection 
by RPR test. 
 Biochemical analysis like S.G.P.T. enzyme level, T.I.B.C. and Serum Iron.  
 Bacteriological analysis like blood culture. 
 Microscopic examinations for detection of malarial parasites  
 Molecular analysis for detection of viral genetic material by PCR technique. 
 Statistical analysis of some of the data obtained was also carried out using 
correlation analysis, two way ANOVA for analysis of some of the results. 
  
Results from all the cohorts were studied and inter-cohort comparison as well as 
comparison with the trend of infection was carried out. Following trends were 
emerging out of our present study: 
 
Donor Cohort  
 Trend is changing from replacement to voluntary donors. The ratio at the 
beginning of the study was 0.41(voluntary/replacement), now it is almost 1 
suggesting that now 50% of the blood comes from voluntary donation. 
 Incidence of microbial markers is increasing even in donor population. 
 Most frequently occurring blood group is blood group B followed by blood 
groups O, A &AB in decreasing order in donor population. 
 
Thalassemic Cohort 
 Thalassemic cohort has higher seropositivity for HIV, HBsAg & HCV 
compared to donors. 
 At the end of the study increase in incidence of HIV & HCV has been 
observed. Seropositivity in terms of percentage for HBsAg is decreased 
suggesting efficiency of vaccination for this marker in thalasemic subjects. 
 About 50% thalassemic patients had spleenomegaly and 14% were 
spleenectomized.  
152 
 
 Hematological & serological parameters show typical microcytic anemia. 
Elevated levels of SGPT was observed but was not always associated with 
seropositivity of hepatitis viral markers. 
 
Hemodialysis Cohort 
 In cohort of hemodialysis patients higher incidence of hepatitis viral markers 
was observed especially hepatitis C. 
 Number of male patients on maintenance hemodialysis was more than female 
patients.  
 There was an increase in the incidence of HBV and HCV infection at the end 
of the study observed.  
 An alarmingly high rate of HCV infection in hemodialysis patients and 
remarkable increase at the end of the study was observed.   
 Other microbial infection like parasitic infection by malarial parasite was 
found in one patient undergoing maintenance hemodialysis. 
 Blood group O and A seem to have predilection for hepatitis C virus infection 
in haemodialysis patients. 
 On an average, number of dialysis was more for HCV positive patients than 
HCV negative patients. 
 Socio-economical parameters such as age & gender were studied. Where 
number of male patients were 64.34% while female patients were 35.65% 
suggesting faster progression of renal failure in males compare to females. The 
age group that was affected most was 20-40 years which comprised more than 
50 %( 52.48%) of the total CRF patients on maintenance hemodialysis. 
 
Haemophilia Cohort 
 Majority of the patients in Hemophilia cohort were suffering from severe 
factor VIII deficiency in the age group of 15 to 30. 
 Lower incidence of HBsAg and HCV marker may be due to excellently 
screened donors for FFP and viral inactivation of factors. 
 CMV infection was more prevalent in hemophilia patient compare to HBsAg 
and HCV seropositivity.  
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 Low socio-economic status of most of the families made the treatment and 
management of the disease even more difficult. 
 
Surgical multitransfused and Leukemia Cohort 
 Bacteriological analysis of surgical multitransfused patient did not reveal 
presence of any bacterial growth in laboratory set up. 
 Incidence of HBsAg and HCV was observed higher from the control results. 
 A small group of multitransfused leukemia patients was also studied with 
respect to socio-economic criteria and microbial infections. 
 There was no seropositivity for HIV, HBsAg and HCV in our subject group. 
 Immunosuppressive treatment makes leukemia patients vulnerable to 
opportunistic pathogens like CMV as shown in our study. 
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CHAPTER 7 
CONCLUSIONS 
 
Donors 
 There is an increased incidence of all the microbial markers among donor 
population suggesting rise in rate of infection in general population. 
 Seropositivity of Hepatitis C virus among general population has increased 
alarmingly from 2002 to 2007. The increase is 5.19 times suggesting rapid 
spread of infection in general population. 
 Trend of voluntary donation of blood has increased steadily from 2002 to 
2007; it is a very welcome result in our study. Healthy voluntary non-
remunerative donors will lead to safe blood supply to the patients.  
 This trend is also reflected in ratio of voluntary to replacement blood donation. 
In 2002 it was only 0.41 which exceeded 1.02 in 2007 suggesting more then 
50% of blood comes from voluntary donation. 
 
Thalassemia 
 Socio-economic studies reflect that number of male patients is more than 
double compared to female patients suggesting bias towards treatment of only 
male children. 
 Thalassemia is most prevalent in scheduled caste followed by Lohana, Muslim 
and Brahmin in decreasing order. Inclusion of Brahmin caste in higher 
incidence category is the new finding of our result. 
 Higher incidence of viral markers such as HIV, HBsAg and HCV compared to 
donor population is indicative of thalassemics being at higher risk of 
Transfusion Transmitted Infections. 
 Incidence of all the three above said markers was compared in the beginning 
and at the end of the study. Rate of HIV and HCV infections was markedly 
high at the end of the study compare to the beginning. However, rate of 
HBsAg infection was not so high suggesting success of immunization program 
against hepatitis B infection. 
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 Haemogram of Thalassemic patients reflect typical picture of Microcytic 
anemia. 
 Elevated levels of S.G.P.T. enzyme in majority of Thalassemic patients 
suggest hepatospleenomegaly due to multiple blood transfusions. However 
higher S.G.P.T. level not necessarily meant seopositivity for Hepatitis B or C 
virus. 
 Because of higher turnover rate of RBCs serum iron levels were higher in 
these patients compare to normal. Total Iron Binding Capacity (T.I.B.C.) was 
also found to be higher in these patients. 
 No seropositivity of transfusion transmitted Syphilis was observed in our 
study. 
 
Hemodialysis 
 Number of male patients with Chronic Renal Failure (CRF) was higher 
compare to the female patients. Our data is in confirmation with earlier 
findings that the rate of progression of renal disease is faster in male than 
female. 
 Distribution of blood groups in Hemodialysis patients is same as normal 
population suggesting no particular relationship between blood group and 
CRF condition. 
 Seropositivity with viral markers mainly Hepatitis B and Hepatitis C is higher 
in CRF patients compared to normal population. 
 An alarmingly high rate of HCV infection in hemodialysis patients and 
remarkable increase at the end of the study i.e. from 30.45% to 40.00% 
suggests need to reexamine all the aspects of possible entry of infectious agent 
into hemodialysis patients right from donor’s screening to spread of infection 
during the process of dialysis to immune status of the patient. 
 Average number of dialysis is also significantly high in HCV positive CRF 
patients compared to HCV negative CRF patients. 
 Other microbial infection like parasitic infection by malarial parasite was 
found in one patient undergoing maintenance hemodialysis. 
 No reactivity was observed for Syphilis by RPR test. 
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 An interesting result was observed with regard to distribution of blood group 
in HCV infected hemodialysis patients in contrast to the normal distribution of 
blood groups in general population. Prevalence of Blood Group O (33.82%) 
was followed by Blood Group A (30.88%), B (26.47%) and AB (5.88%) in 
decreasing order. Higher rate of infection in Blood Group A patients is 
reported in our study. 
 
Hemophilia 
 Comparable with literature data Factor VIII deficiency was most prominent in 
our subjects followed by Factor IX and other factors. 
 Maximum number of Hemophilia patients was in the age group of 15-30 
years. Number of young patients was least, suggesting good prenatal 
counseling. Survival of 16% patients above the age of 31 years suggests good 
management of the disease.  
 Most of the patients had a relatively high factor requirement as shown in our 
study. This suggests severe hemophilia is prevalent in our cohort of study. 
 Blood group B and O were almost equivalently prevalent. 
 Family income of most hemophilic patients was not enough to be able to 
afford costly factor replacement therapy so most of them are dependent on 
Fresh Frozen Plasma (FFP) instead of pure factor thereby increasing risk of 
transfusion transmitted infections. 
 CMV infection was more prevalent in hemophilia patient compared to HBsAg 
and HCV seropositivity. Good donor selection for FFP explains lower 
seropositivity for HBsAg and HCV. Immunocompromised status of these 
patients explains higher CMV infections.  
 
Surgical multitransfused and Leukemia 
 Males are more prone to accidental injury leading to multiple blood 
transfusions. In female patients, gynecological and obstretic surgery is one of 
the major conditions requiring multiple blood transfusions. 
 Young people in the age group of 20-30 years comprise of more than 50% of 
surgical multitransfused patients in our study. 
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 Bacteriological analysis of surgical multitransfused patient did not reveal 
presence of any bacterial growth in laboratory set up. This could be because of 
the usual prescription of broad-spectrum antibiotics to the patients and 
bactericidal property of the blood. 
 Incidence of HBsAg and HCV was higher from the control results suggesting 
multiple blood transfusions as high risk activity. However, no seropositivity of 
HIV marker was observed in our study. 
 A small group of multitransfused leukemic patients was also studied with 
respect to socio-economic criteria and microbial infections. 
 Most of these patients belong to lower middle income group.  
 There was no seropositivity for HIV,HBsAg and HCV in our subject group. 
 Immunosuppressive treatment makes leukemia patients vulnerable to 
opportunistic pathogens like CMV as shown in our study. 
 
General Conclusions 
Comparative data of viral markers in various cohorts of multitransfused patients show 
variable results. This could be because of many reasons. Few of them are listed 
below. 
 Different immune status. 
 Variable number of transfusions. 
 Type of blood component. 
 Source of Blood. 
 Socio-economic parameters. 
 
Among different cohorts incidence of viral markers were as follows 
 Higher rate of HIV seropositivity was found in Thallaesamic patients 
compared to control population. 
 HBsAg seropositivity was highest in Hemodialysis patients followed by 
Thalassemics and Surgical multitransfused patients respectively, least being in 
Hemophiliacs. 
 Alarmingly high rate of infection by HCV is in Hemodialysis patients, second 
but distinctively far is Thalassemic children followed by surgical 
multitransfused patients. 
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 CMV infections were an alarming 30% in Leukemia patients and 1.29% in 
Hemophiliacs. 
 Presence of Malarial parasite P. falciparum was observed in one hemodialysis 
patient. 
 As regard to examination of blood samples from these patients no reactivity 
with RPR test was observed. 
 No blood culture was found conclusively positive suggesting low prevalence 
of bacteria in blood. This could be attributed to bactericidal activity of blood 
components in stored blood. 
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